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Functional Characterization of Cytochrome b5 Reductase and its Electron Acceptor 
 Cytochrome b5 in Plasmodium falciparum 
Lucio Malvisi 
ABSTRACT 
 
Malaria is a disease of major public health importance, killing approximately one 
million people and causing about 250 million cases of fever annually.  It mostly affects 
children under the age of five and pregnant women in many developing countries, 
making it a prominent issue in international health and maternal and child health.  The 
most aggressive form of malaria is caused by the parasite Plasmodium falciparum which 
is responsible for 80% of infections and 90% of deaths from malaria, and is most 
prevalent in sub-Saharan Africa.  
Public Health interventions include the implementation of prevention programs, 
health education, and chemotherapy.  The latter has experienced multiple problems in the 
past years whereby resistance of the parasite to the available drugs has emerged, 
rendering the majority of them ineffective.  Furthermore, the high cost of those drugs 
represents a major obstacle to their dispensation in areas of the world where the affected 
people are often the less fortunate.  The enzyme Cytochrome b5 Reductase (cb5r) and its 
electron acceptor Cytochrome b5 (cb5) play a role in fatty acid elongation, cholesterol 
biosynthesis, and cytochrome P450-mediated detoxification of xenobiotics. Therefore, 
these proteins are suitable as potential novel drug targets for malaria.  These two proteins 
have been thoroughly studied in mammals but have to be characterized in 
microorganisms such as fungi and parasites, including Plasmodium falciparum. It is 
ix 
 
important to note that plant cb5r has been identified as a novel herbicidal target.  
Considering the close phylogenetic relationship between plant cb5r and Plasmodium 
falciparum cb5r, we conclude that these plant inhibitors may also serve as promising 
candidates for a new class of antimalarial drugs against the parasite. 
In this project, we want to obtain the biochemical and enzymatic characterization 
of cb5r and cb5 in order to establish whether these two proteins represent potential novel 
drug targets in Plasmodium falciparum malaria.  
This initial work may lead to the development of novel drugs which will 
consequently affect the field of public health with respect to drug delivery, drug 
resistance, and drug chemotherapy.     
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INTRODUCTION 
 
Malaria 
 
 
Malaria is an infectious disease caused by a parasite called Plasmodium, which is 
transmitted via the bites of infected mosquitoes.  Symptoms of malaria include fever, 
headache, and vomiting, and usually appear between 10 and 15 days after the mosquito 
bite.  If not treated, malaria can quickly become life-threatening by disrupting the blood 
supply to vital organs (WHO, 2009).  Each year approximately 500 million cases and 
over one million deaths occur worldwide (mainly among children under five years of 
age), the majority being reported in Africa south of the Sahara.  These numbers make 
malaria one of the most important neglected diseases and a major field of action for 
public health organizations and authorities.  A key fact is that there are incredible 
margins of improvement in terms of reduction of number of cases and deaths and this 
could be achieved by applying simple preventive measures.  However, the malaria burden 
faces tons of issues that have impeded the regular application of those measures.  Among 
these, the lack of funding for the development of a vaccine and of new drugs, the 
insurgence of drug resistance, the lack of education and the cultural obstacles of the 
affected populations have all played an unfavorable role in the fight against malaria.  All 
these factors are deeply related as we will discuss later. 
 
History 
 
  
 The word malaria comes from the Italian mala aria, meaning bad air, because it 
was associated with swamps and marshland.  The disease was probably first described by 
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the Chinese in 2700 BC and then again by the Greeks in the 4th century BC where it was 
partially responsible for the decline of their empire.  But it was again in China where a 
plant, named Qinghao plant, was first discovered; this plant showed very promising anti-
fever properties in people affected and it represented the only available cure for malaria 
for centuries.  The active ingredient of Qinghao was isolated by Chinese scientists in 
1971. Known as artemisinin, it is today a very potent and effective antimalarial drug, 
especially in combination with other medicines.  Another drug that has served as one of 
the few known remedies to treat malaria was quinine, which was derived from the bark of 
a plant discovered by the Spanish conquistadores in Peru.  Along with artemisinin, 
quinine is still one of the most effective drugs available today.  
 The discovery of the parasite that causes malaria was made in 1880 by Charles 
Louis Alphonse Laveran, a French surgeon who noticed the presence of the parasites in 
the blood of a patient and for which he was awarded the Nobel Prize.  Then, an Italian 
doctor, Camillo Golgi, found that there were different types of parasites that caused 
malaria, one that exhibited tertian periodicity (fever every three days) and one that 
showed a quartan periodicity (fever every four days).  He also observed that the 
insurgence of fever corresponded to the rupture and release of merozoites (the liver stage 
of the parasite) into the blood.  Other scientists named the various species of the parasite 
until the American scientist William Welch in 1897 named the malignant tertian malaria 
parasite, Plasmodium falciparum (CDC, 2004).  Ever since, the prevalence of malaria has 
been steadily increasing despite the efforts of various public health agencies acting at 
local, national, and international level, to control and prevent the spread of the disease.  
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Over the past twenty years the annual cases of malaria have constantly raised and 
it is predicted that this trend will not slow down in the next years. The goal of reaching 
eradication that was proposed in the past years has appeared to be little realistic, therefore 
the current target is to achieve control of the disease.  
 
Funding and Financial Contributions 
 
  
Thankfully, funding for malaria that comes from international organizations, 
federal agencies, global funds, and the governments of wealthy nations have substantially 
increased in the past few years (Table 1 & Fig. 1) (Roll Back Malaria, 2005).  The 
“Global Fund to fight AIDS, Tuberculosis, and Malaria” (GFATM), the European Union, 
the President’s Malaria Initiative (PMI), the “World’s Bank Booster Program for Malaria 
Control in Africa”, and the new French-led UNITAID are some of the main contributors 
in the fight against malaria (European Alliance against Malaria, 2007).  Moreover, the 
intervention through personal funding by generous people has also occurred.  These 
people have decided to offer their wealth in the fight against neglected diseases, as in the 
case of Bill Gates who founded, together with his wife, “The Bill and Melinda Gates 
Foundation”.  Its goal is to help create a more equal world, without the burden of those 
infectious diseases that affect the most disadvantageous areas of the world and the most 
vulnerable people (Bill and Melinda Gates Foundation, 2009). 
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Table 1: Estimated contributions to malaria control activities by development 
agencies.  (Roll Back Malaria, 2005) 
 
 
Figure 1: Estimated contributions to malaria control activities by development 
agencies (US$).  (Roll Back Malaria, 2005) 
 
Also in the Roll Back Malaria report, we see similar trends in the allocation of 
money that is made available for research in malaria.  Analyzing the situation of the past 
few years, we notice that funds have been more and more abundant every year and in 
every aspect of the fight against malaria.  Contributions from development agencies have 
targeted not only the governments of the countries where malaria is present, but also 
reached out to NGOs, research and development in malaria control, and other 
organizations such as Roll Back Malaria, the Malaria Consortium, and the Special 
Program on Research and Training in Tropical Diseases.  Another important aspect is that 
funds also increased in terms of availability in different geographic regions; all affected 
regions on earth saw their resources reach very promising levels.  In particular sub-
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Saharan Africa, the area of the world where the majority of cases and deaths occur and 
where most of the fatalities are caused by the most aggressive of the malaria parasites, 
namely Plasmodium falciparum, experienced an exponential development in the funds 
donated by agencies (Table 2) (Roll Back Malaria, 2005).  This really has a positive 
impact on the lives of millions of people that live in endemic areas; it is also a sign that 
the strategy and the administration of the budget is well organized because funding is 
going where it is most needed and dispersion of money, a common issue in the delivery 
of funds to the proper recipients, is widely avoided. 
 
Table 2: Funding by region (US $).  (Roll Back Malaria, 2005) 
When looking at the data in Table 2 or many other tables of data collected by 
international organizations, we realize that the huge difference in funding between 1999 
and 2004 (the most striking numbers are observed in the sub-Saharan African region) is 
certainly not reflected by the crude figures of number of new cases and deaths.  In 2005, 
the World Health Assembly determined to ‘ensure a reduction in the burden of malaria by 
at least 50% by 2010 and by 75% by 2015’.  This resolution has been interpreted to mean 
a reduction in morbidity as well as mortality.  
 
 
 
 
6 
 
Prevention, Control, and Cure 
 
 
We are facing a worldwide burden that’s causing the death of millions of people 
every day and it is mainly affecting the most vulnerable part of the population, namely 
children and pregnant women.  Current public health measures of prevention and control 
have served of little help in spite of their excellent, at least theoretically, applicability. 
Public health authorities are acting on any possible form of prevention and control, 
attacking the problem with aggressive actions, however each procedure often encounters 
difficulties.  These can be due to drug resistance in the development of a new drug or 
drug target, mosquitoes that have become resistant to insecticides, or the implementation 
of new programs that go against cultural practices to name a few. 
Another very striking number that is closely associated to those just mentioned is 
the coverage of the population with curative and preventive measures such as 
Artemisinin-based Combination Therapy (ACT) and Insecticide-treated Bed Nets (ITN), 
respectively.  Considering 2005 as the baseline year for the evaluation of the results 
obtained with the implementation of the new strategies and directives set by the WHO, 
such as control programs, epidemiological surveillance, health policies and health system 
structure, the target is to reach a coverage of over 80% of the population by 2010.  It is a 
very complicated scenario and the data obtained from the surveillance reports of many 
countries are contradictory, often due to unreliable data collection.  Between 2001 and 
2006, many countries in Africa experienced a growth in cases and deaths even though 
this may be due to improved surveillance or more complete records for those years.  On 
the other hand, a few other African countries such as Eritrea, Madagascar, and Rwanda, 
achieved high coverage of interventions and saw cases and deaths diminished (Fig. 2).  
7 
 
 The scenario in terms of curative and preventive measures in Africa is very 
variegated and difficult to interpret.  But thanks to an improved epidemiological 
surveillance and more thorough records, more reliable data will be available in the future 
that will enable us to draw more accurate conclusions.  
 
 
Figure 2: Trends in malaria cases (inpatients and outpatients) and deaths 
(inpatients) in relation to intervention, 2001 – 2006 (NMCP data).  (WHO, 2008) 
These are two clear examples of how the start of the implementation of malaria control programs, such as 
the distribution of insecticide-treated nets (ITN), indoor residual spraying (IRS), long-lasting insecticidal 
nets (LLIN), and artemisinin-based combination therapy (ACT) coincide with a stunning decrease in the 
number of cases and deaths. 
 
Outside Africa, the picture is similar.  In a few countries of Central and South 
America, the reduction in malaria has coincided with improved policies on malaria 
control; these included efficient surveillance and early case detection to prevent and 
contain epidemics, integrated vector management, prompt diagnosis and treatment, and 
health system strengthening.  In the WHO Eastern Mediterranean Region, the countries 
that have shown the greatest reductions in malaria are those where National Malaria 
Control Programs (NMCPs) have strong political and financial support from the 
government, and which operate within health systems that are well developed at the 
central and peripheral level.  As we can see, the available data do not allow us to draw 
definite conclusions about the efficacy of the whole range of activities being 
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implemented and developed by the partnership between various international 
organizations and programs.  
An important aspect is that the process of reduction of the incidence of malaria in 
successful countries was guaranteed by a more advanced political and economic status. 
On the other hand, the absence of a firm and little corrupted head of state, the 
devastations caused by never-ending civil and military conflicts, the simultaneous 
presence of other deadly diseases, a history of centuries of subordination to colonial 
empire, and the scarcity of natural resources have impeded a decent administration of the 
malaria control interventions in certain countries such as Burkina Faso, Nigeria, Senegal, 
and Ghana.  Here the predispositions to a well-rounded execution of preventive and 
control measures are absent, therefore the logical outcome was an increase in the cases 
and deaths from malaria over the last few years (Table 3).  
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Table 3: Reported malaria deaths, 1990-2007. (WHO, 2008) 
From the table we notice the increase in deaths in the countries just mentioned: Burkina Faso, Nigeria, 
Senegal, and Ghana where certain conditions such as lack of leadership, corruption, war, and extreme 
poverty prevented the malaria control programs from being successful. 
 
In an effort to a comprehensive fight against malaria, WHO has also identified 
four programmatic phases on the way to achieving and maintaining elimination: control, 
pre-elimination, elimination, and prevention of reintroduction (Fig. 3) (WHO, 2008). 
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Figure 3: Steps from malaria control to elimination.  (WHO, 2008) 
 
According to this scheme, countries make the transition from control to the pre-
elimination phase when less than 5% of all suspected malaria cases have a laboratory 
confirmation of malaria.  The elimination phase begins when there is less than 1 malaria 
case per 1000 people at risk per year.  Elimination is achieved when the “prevention of 
reintroduction”, without local transmission by mosquitoes, has been successful for three 
or more consecutive years (WHO, 2008). 
 
Analysis of Goal 6 of the Millennium Development Goals: Combat HIV/AIDS, malaria 
and other diseases.  Interestingly, Goal 6 of the Millennium Development Goals, which 
foresees the eradication of malaria by 2015, is falling short of global targets.  Here, the 
two main means to reduce the incidence of malaria are considered 1) prevention through 
a higher distribution and use of insecticide-treated mosquito nets and 2) treatment 
through the use of antimalarial medicines.  In particular the United Nations are now 
tending to shift their focus and interest on the artemisinin-based combination therapy, 
especially in sub-Saharan Africa where resistance to traditional drugs has developed.  But 
“There has been less progress in treating malaria than in preventing it” UN officials say 
in their last report in August 2008.  In fact, according to data gathered from 2000 to 2006, 
the use of insecticide-treated mosquito nets has increased (Fig. 4a) (even though not with 
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the impressive figures the organization was expecting), while the proportion of children 
with fever who have received antimalarial medicines in 2006 has declined in comparison 
with the 2000 figures.  Even more stunningly, treatment with ACT is, in general, still at 
extremely low levels, even though it has shown hopeful signs of growth since 2005 (Fig. 
4b).  Funding for the more expensive ACT is recent but has increased markedly since 
2005; moreover, the implementation of programs that try to promote the use of ACT as 
standard treatment for malaria is just a recent shift, therefore the governments and the 
ministries of health of the affected nations are slowly but effectively mandating the 
introduction of this fairly new line of treatment.  In general, evidence suggests that both 
the increased distribution of insecticide-treated nets and household spraying, and the use 
of antimalarial medicines are giving promising results in the reduction of cases and 
deaths from malaria around the world, even though the idea of eradication by 2015 seems 
to be rather utopist (United Nations, 2008). 
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Figure 4a: Proportion of children sleeping under insecticide-treated bed nets in 
selected countries, around 2000 and 2006 (Percentage).  (United Nations, 2008) 
 
Figure 4b: Number of doses of artemisinin-based combination therapies procured 
worldwide, 2003-2006 (Millions).  (United Nations, 2008) 
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In 2007 the European Alliance against Malaria said that there is an estimated 
global requirement of about US$ 3.2 billion a year to make sure malaria is eradicated by 
2015.  However, at present less than US$ 1 billion per year is available for malaria 
resources (European Alliance against Malaria, 2007).  All the elements needed for a 
successful eradication, such as funding, research, leadership, experience, awareness, and 
dedication are present but need to be used wisely.  The results are promising.   
Etiology 
 
Malaria is caused by obligate intracellular protozoan parasites of the genus 
Plasmodium.  They are members of the class Sporozoa, therefore alternating asexual and 
sexual reproductive cycles are observed. 
There are currently over 200 species in the genus, of which at least ten infect humans 
but only five are known to cause malaria in humans:  
• Plasmodium falciparum: found in tropical regions and not established in colder 
climates; causes the most severe and fatal disease. 
• Plasmodium vivax: most common and widely distributed (subtropical and 
temperate) malarial parasite; relapsing malaria.  
• Plasmodium malariae: limited to subtropical areas.  This species is less common 
than P. falciparum or P. vivax.  
• Plasmodium ovale: the least common malarial species, usually found in Africa; 
relapsing malaria. 
• Plasmodium knowlesi: causes malaria in macaques but can also infect humans. 
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Plasmodium falciparum has the highest rate of mortality.  It is also responsible for 
80% of malarial infections and 90% of deaths.  Episodes of infection and death from P. 
falciparum occur mainly in sub-Saharan Africa. 
P. vivax is less virulent than P. falciparum and usually not fatal.  Sometimes death is 
observed due to splenomegaly, a pathologically enlarged spleen.  Its distribution 
comprises Asia, Latin America, and some parts of Africa.  
P. malariae causes a ‘benign malaria’ and it is not nearly as dangerous as the 
infections caused by P. falciparum and P.vivax.  It is found worldwide from sub-Saharan 
Africa to Southeast Asia, the islands of the Western Pacific, and the Amazon Basin of 
South America.  It is also the least studied of all five malaria-causing parasites due to its 
low prevalence and milder clinical manifestations. 
P. ovale is very limited in its distribution; it is endemic mainly in West Africa, the 
Philippines, Eastern Indonesia, and Papua New Guinea.  It is considered less virulent than 
P.falciparum and P. vivax.  
P. knowlesi is a primate malaria parasite commonly found in Southeast Asia.  As 
mentioned, it primarily causes malaria in macaques but it can also infect humans, 
especially those who work in the rain forest.  With the increasing amount of deforestation 
in Southeast Asia, the macaques are now coming in close contact with humans, therefore 
even the people that live in semi-urban areas are now found to be infected with P. 
knowlesi.  The first case of a natural infection with P.knowlesi was reported in 1965 in an 
American man who visited the Malaysian rainforest. P.knowlesi accounts for up to 70% 
of cases of malaria in Southeast Asia.  This parasite is not prevalent in West Africa.  This 
may be due to the fact that West African populations lack the Duffy antigen, a protein on 
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the surface of red blood cells (RBC) that the parasite uses to start the invasion (National 
Institute of Health, 2000).  
 
Vector and Transmission  
 
 
Malaria is transmitted to humans through the bite of infected female anopheles 
mosquitoes.  Anopheles is the only recognized genus of mosquitoes that is able to 
transmit the parasite Plasmodium with the consequent development of malaria in the 
host.  Of the 460 recognized species of anopheles, approximately 60 have been identified 
as vectors for malaria.  Anopheles gambiae is probably the best known vector because of 
its ability to transmit the deadly Plasmodium falciparum, and it is also the most abundant 
vector in Africa together with A. funestus.  The vector in North America is Anopheles 
freeborni.  In India, approximately 45 mosquitoes have been identified to be vectors or at 
least potential vectors for malaria; among these, the most prominent are A. fluviatilis and 
A. minimus which are found in the foot-hill regions, A. stephensi and A. sundaicus which 
are numerous in the coastal regions and A. culicifacies and A. philippinensis which are 
characteristic of the plains (Fig. 5) (Malaria Site, 2007).  
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Figure 5: Global Distribution of Dominant or Potentially Important Malaria 
Vectors.  (Kiszewski et al., 2004) 
 
Understanding the biology and behavior of Anopheles mosquitoes can help 
understand how malaria is transmitted and can aid in designing appropriate control 
strategies.  One very important aspect in terms of the biology and behavior of anopheles 
mosquitoes is that different species have different capacities to successfully carry and 
transmit the parasite to humans.  Some have immune mechanisms that encapsulate and 
kill the parasites after they have invaded the mosquito stomach wall (Tahar et al, 2002).  
This ability of the mosquito immune system to identify and attack the parasites renders 
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the mosquito refractory to the parasite and does not facilitate the transmission of the 
disease, a fundamental characteristic in terms of public health control measures.  In fact, 
there have been studies where this immune response mechanism has been analyzed with 
the hope of producing genetically modified mosquitoes that are refractory to malaria and 
that will replace the wild ones, thereby limiting the transmission of malaria.  In particular, 
scientists have found that the C-type lectin CEL-III from Cucumaria echinata, a sea 
cucumber found in the Bay of Bengal, impaired the development of the parasite 
Plasmodium when produced in genetically modified A. stephensi (Yoshida et al., 2007). 
This and further studies are setting up the base for the creation of transgenic mosquitoes 
with the goal of replacing them with the wild mosquitoes; this would be considered a 
huge relief in the efforts that are being made in the control and prevention of malaria and 
it is a sort of revolution in how the methods used to fight malaria are viewed.   This 
would be considered a victory over malaria by molecular biology rather than public 
health (CDC, 2008).  
Other behavioral characteristics that influence the transmission of malaria and that 
have implications on the design of control programs are 1) the sources of blood and its 
relation to the time required for the development of the parasite in the mosquito, 2) the 
patterns of feeding, and 3) insecticide resistance.  These elements are explained as 
follow:  
1)  It is known that some mosquitoes are anthropophilic and feed on humans while others 
are zoophilic and feed on animals.  The two major species found in Africa, A. gambiae 
and A. funestus, are strongly anthropophilic.  The next necessary process that has to take 
place in order for the transmission cycle to continue, is the development of the parasite 
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within the mosquito.  This process is known as extrinsic incubation period and it ranges 
from 10 to 21 days, depending on the parasite species and the temperature at which it 
develops.  If a mosquito does not live long enough to allow for parasite development, the 
transmission cannot occur.  Since it is not feasible to measure the life span of mosquitoes 
in nature, researchers estimated that the rate of survivorship in A. gambiae in Tanzania 
ranged between 0.77 and 0.84, meaning that at the end of one day between 77% and 84% 
will have survived.  Assuming that this survivorship is constant throughout the adult life 
of a mosquito, less than 10% of female A. gambiae would survive longer than a 14-day 
extrinsic incubation period (CDC, 2008).        
 2) Anopheles mosquitoes are crepuscular (active at dawn or dusk) or nocturnal (active at 
night).  They enter the house between 5 p.m. and 9.30 p.m. and again in the early hours of 
the morning.  They start biting by late evening and the peak of biting activity is at 
midnight and early hours of the morning.  Anopheles mosquitoes can be usually 
differentiated into endophagic/endophilic (mosquitoes which prefer to feed indoors and 
rest indoors after feeding) and exophagic/exophilic (those which prefer to feed outdoors 
and rest outdoors after feeding); the biting pattern of the first group can be easily 
prevented by indoor spraying of insecticides while the activity of the second category is 
controlled through the destruction of the breeding sites (Malaria Site, 2007). 
3) Insecticides are used in the two most efficacious methods of control recommended by 
the WHO and implemented by the ministries of health and local authorities of malaria-
endemic nations: indoor residual spraying and insecticide-treated nets.  Unfortunately, 
mosquitoes throughout the planet have shown various levels of resistance to all 
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insecticides available.  According to the CDC, there are over 125 mosquito species with 
documented resistance to one or more insecticides (CDC, 2008).  
Since resistance is a fundamental aspect in control program planning, resistance 
management has become an integral part of resistance surveillance.  As a consequence, 
program planning can also be more proficient with an efficient surveillance.  If for 
example, a certain vector is no longer considered susceptible to DDT based on field 
surveillance and subsequent verification with molecular tools, then an alternative 
insecticide may be used in that particular area.  Moreover, if the vector shows some 
resistance to a particular insecticide, it does not mean that control activities are 
compromised.  Resistance to a particular insecticide must be high enough not to have any 
effect on preventing transmission.  A good example that delineates this case scenario was 
Western Kenya, where resistance to pyrethroid applied to bed nets appeared soon after 
their introduction and was calculated to be approximately 10% of the vector population.   
After a couple of years, the levels of resistance were still the same, therefore no changes 
in control policies were necessary (Brogdon & McAllister, 1998). 
 The current available insecticides are DDT, pyrethroids (deltamethrin and 
permethrin), bendiocarb, and malathion.  Mosquitoes have shown some degree of 
resistance to all of these.  The most widely used in recent years have been pyrethroids 
because of their low toxicity and relative safety for humans, but resistance, particularly in 
the application to ITNs, has become a growing problem throughout Africa (Kerah-
Hinzoumbè et al., 2008).  Furthermore, cases of cross-resistance to DDT and pyrethroids 
have been documented.  This occurred because these two chemicals have a similar mode 
of action and act on the same target, namely the sodium channels of the nerve sheath.  In 
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order to deal with an increasing level of resistance to our available insecticides, it is 
imperative that we establish a well-organized system of early detection and constant field 
surveillance for resistance and that we make progress in those molecular genetics studies 
that will lead us to a deeper understanding of how resistance arises and maintains in 
populations (Brogdon & McAllister, 1998). 
Life Cycle 
 
 
 
Figure 6: Life Cycle of Malaria.  (CDC, 2006) 
  
 
The malaria parasite life cycle involves two hosts.  During a blood meal, a 
malaria-infected female Anopheles mosquito inoculates sporozoites into the human host 
. Sporozoites infect liver cells  and mature into schizonts , which rupture and 
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release merozoites .  (Of note, in P. vivax and P. ovale a dormant stage [hypnozoites] 
can persist in the liver and cause relapses by invading the bloodstream weeks, or even 
years later).  After this initial replication in the liver (exo-erythrocytic schizogony ), the 
parasites undergo asexual multiplication in the erythrocytes (erythrocytic schizogony ). 
Merozoites infect red blood cells .  The ring stage trophozoites mature into schizonts, 
which rupture releasing merozoites .  Some parasites differentiate into sexual 
erythrocytic stages (gametocytes) .  Blood stage parasites are responsible for the 
clinical manifestations of the disease.  
The gametocytes, male (microgametocytes) and female (macrogametocytes), are 
ingested by an Anopheles mosquito during a blood meal .  The parasites’ multiplication 
in the mosquito is known as the sporogonic cycle .  While in the mosquito's stomach, 
the microgametes penetrate the macrogametes generating zygotes .  The zygotes in turn 
become motile and elongated (ookinetes)  which invade the midgut wall of the 
mosquito where they develop into oocysts .  The oocysts grow, rupture, and release 
sporozoites , which make their way to the mosquito's salivary glands.  Inoculation of 
the sporozoites  into a new human host perpetuates the malaria life cycle (CDC, 2006). 
 
Public Health Impact  
 
  
 Malaria is one of the most severe public health problems worldwide and a leading 
cause of death and illness in many developing countries.  According to the last ‘World 
Malaria Report 2008’ there were an estimated 247 million malaria cases among 3.3 
billion people at risk in 2006, causing nearly a million deaths, mostly of children under 5 
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years. 109 countries were endemic for malaria in 2008, of which 45 were within the 
WHO African Region (WHO, 2008).  Other significant figures: 
Malaria Cases: 
- 91% or 230 million cases were due to Plasmodium falciparum 
- 86% of all cases occurred in the African Region, followed by South-East Asia 
(9%) and the Eastern Mediterranean Region (3%) 
- The percentage of cases due to P. falciparum exceed 75% in most African 
countries but only in a few countries outside Africa 
- In Africa, 19 of the most populous countries accounted for 90% of estimated 
cases in 2006 
Malaria Deaths: 
- There were an estimated 881.000 deaths worldwide in 2006, of which 90% in the 
African Region and 4% in each of the South-East Asia and Eastern Mediterranean 
Region 
- An estimated 85% of deaths occur in children under 5 years, but the proportion is 
much higher in the African (88%) and Eastern Mediterranean regions (76%) than 
in other regions (16-40%) 
- Eighteen countries accounted for 90% of deaths in the African Region, and seven 
countries had 90% of deaths outside the African Region, dominated by Sudan and 
India 
So which are the most affected groups of the population?  For the most part children 
under the age of five who have not yet developed immunity to malaria, pregnant women, 
whose immunity is decreased by pregnancy, especially during the first and second 
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pregnancies, and travelers or migrants coming from areas with little or no malaria 
transmission who lack immunity.  
A central factor that contributes to the expansion of the burden of malaria is the 
infection during pregnancy.  Malaria can have adverse effects on both the mother and the 
fetus.  Health consequences include maternal anemia, fetal loss, premature delivery, 
intrauterine growth retardation, and delivery of low birth-weight infants (<2500 g or <5.5 
pounds).  The health condition that an infection causes differ according to the type of 
malaria transmission area.  There are two types of transmission areas: stable (high) or 
unstable (low). 
 
- In high transmission areas, women have gained a level of immunity to malaria 
that wanes somewhat during pregnancy.  Malaria infection is more likely to result 
in severe maternal anemia and delivery of low birth-weight infants.  
- In low transmission areas, women generally have developed no immunity to 
malaria.  Malaria infection is more likely to result in severe malaria disease, 
maternal anemia, premature delivery, or fetal loss. 
In sub-Saharan Africa, the region of the world with the highest incidence of 
malaria, infections are estimated to cause 400,000 cases of severe maternal anemia and 
75,000-200,000 infant deaths annually.  Maternal anemia contributes significantly to 
maternal mortality and causes an estimated 10,000 deaths per year.  Low birth weight is 
the greatest risk factor for neonatal mortality and a major contributor to infant mortality.   
Although many factors contribute to low birth weight, malaria is a major factor and one 
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of the few, along with poor nutrition, anemia, and other infections, that is amenable to 
intervention once a woman becomes pregnant (CDC, 2004; Steketee et al., 2001). 
 In an effort to combat this problem, the World Health Organization currently 
recommends a three-pronged approach to prevent these adverse effects in areas of Africa 
with high levels of transmission of Plasmodium falciparum malaria: 
 
1. Intermittent preventive treatment (IPT) with antimalarial drugs 
2. Insecticide-treated bed nets (ITN) 
3. Febrile malaria case management 
 
One very important point that’s worth to be mentioned here is that the available 
health information for much of sub-Saharan Africa is of very poor quality.  The annual 
estimates provide a useful tool that greatly aids in the types, number, and extensiveness 
of malaria control initiatives but there has been skepticism about their origin and validity. 
Therefore, all present approximations are derived from evidence-based approaches that 
provide greater credibility to malaria control projects (Snow et al., 1999).  Often times 
estimates of the number of malaria deaths are made by: (1) multiplying the estimated 
number of P. falciparum malaria cases by a fixed case-fatality rate for each country; or 
(2) from an empirical relationship between measures of malaria transmission risk and 
malaria-specific mortality rates (WHO, 2008). 
Rank Cause 
Numbers 
(thousands 
per year) 
% of all 
deaths 
1 Neonatal causes  3,910 37 
2 Acute respiratory infections 2,027 19 
3 Diarrheal diseases 1,762 17 
4 Malaria 853 8 
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5 Measles 395 4 
6 HIV/AIDS 321 3 
7 Injuries 305 3 
 Other causes 1,022 10 
 Total 10,596 100.0 
 
Table 4: Leading Causes of Death in Children Under Five Years of Age, Estimates 
for 2000-2003.  (WHO, 2005) 
 
 
Clinical Features 
 
 
 Infection with malaria parasites may result in a wide variety of symptoms, 
ranging from absent or very mild symptoms to severe disease and even death (CDC, 
2006).  In general, malaria presents itself as a febrile illness characterized by fever and 
related symptoms (Malaria Site, 2006).  The incubation period can range from 7 to 30 
days, the shortest time being typically associated with P. falciparum and the longest 
interval with P. malariae.  In the case where antimalarial drugs are being taken for 
prophylaxis and in the event of an infection with P. vivax or P. ovale, the incubation 
period can even reach months or years because these two parasites can produce dormant 
liver stages and reactivate after months or even years after the first manifestation, a 
physiological process known as relapse. 
 Malaria can be categorized as uncomplicated and severe (complicated).  In the 
uncomplicated malaria a typical attack lasts about 6-10 hours.  It consists of: 
- a cold stage (sensation of cold, shivering) 
- a hot stage (fever, headaches, vomiting; seizures in young children) 
- a sweating stage (sweats, return to normal temperature, tiredness). 
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Attacks occur every second day with tertian parasites (P. falciparum, P. vivax, 
and P. ovale), every third day with the quartan parasite (P. malariae), whereas a 
quotidian fever (every day) is observed in P. knowlesi.  Additional clinical manifestations 
of P. falciparum include mild jaundice, enlargement of the liver, and increased 
respiratory rate.  In countries where cases of malaria are infrequent, the typical symptoms 
may be attributed to influenza, a cold, or other common infections, especially if malaria 
is not suspected.  Conversely, in countries where malaria is frequent, residents often 
recognize the symptoms as malaria and treat themselves without seeking diagnostic 
confirmation ("presumptive treatment"). 
Severe malaria occurs when P. falciparum infections are complicated by serious 
organ failures or abnormalities in the patient's blood or metabolism.  The manifestations 
of severe malaria include: 
- Cerebral malaria, abnormal behavior, impairment of consciousness, seizures, 
coma, or other neurologic abnormalities  
- Severe anemia due to hemolysis (destruction of the red blood cells)  
- Hemoglobinuria (hemoglobin in the urine) due to hemolysis  
- Pulmonary edema (fluid buildup in the lungs) or acute respiratory distress 
syndrome (ARDS), which may occur even after the parasite counts have 
decreased in response to treatment  
- Abnormalities in blood coagulation and thrombocytopenia (decrease in blood 
platelets)  
- Cardiovascular collapse and shock  
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Severe malaria occurs most often in persons who have no immunity to malaria or 
whose immunity has decreased.  These include all residents of areas with low or no 
malaria transmission, and young children and pregnant women in areas with high 
transmission (CDC, 2006). 
 
Pathophysiology 
 
 
 An important and fairly new concept in describing malaria is that of a 
multisystem disorder even when the clinical manifestations appear to involve a single 
organ, such as the brain or the liver.  For instance, metabolic acidosis that is often 
observed in severe cases of malaria, such as cerebral malaria or malarial anemia, may 
lead to a syndrome of respiratory distress (Taylor et al., 1993).  In most cases, this is 
predominantly (but not exclusively) a lactic acidosis (English et al., 1996).  To emphasize 
the complexity, variety, and complementary nature of clinical and molecular events of 
malaria, it was determined that lactic acidosis in children has multiple causes: from 
increased production by parasites, through direct stimulation by cytokines, to decreased 
clearance by the liver.  However, most significantly by far is likely to be the combined 
effects of several factors in reducing oxygen delivery to tissues (English et al., 1997).  
A second characteristic is that there is no simple one-to-one correlation between 
clinical syndromes of severe disease and pathogenic processes.  As a result, severe 
anemia may arise from multiple poorly understood processes, including acute hemolysis 
of uninfected RBCs and dyserythropoiesis, as well as through the interaction of malaria 
infection with other parasite infections and with nutritional deficiencies (Newton et al., 
1997).  
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 But how does the infection begin at the physiological level?  Mosquitoes inject 
parasites (sporozoites) into the subcutaneous tissue and less frequently directly into the 
bloodstream; from there, sporozoites travel to the liver.  Recent evidence indicates that 
sporozoites pass through several hepatocytes before invasion is followed by parasite 
development (Mota et al., 2001).  The co-receptor on sporozoites for invasion involves, 
in part, the thrombospondin domains on the circumsporozoite protein and on 
thrombospondin-related adhesive protein.  These domains bind specifically to heparin 
sulfate proteoglycans on hepatocytes in the region in apposition to sinusoidal 
endothelium and Kuppfer cells (Frevert et al., 1993).  Within the hepatocyte, each 
sporozoite develops into tens of thousands of merozoites, each able to invade a RBC 
upon release from the liver.  Disease begins only once the asexual parasite multiplies 
within RBCs.  This is the only gateway to disease.  P. falciparum and P. vivax within 
RBCs develop over 48 hours, producing around 20 merozoites in a mature parasite, each 
able to invade other RBCs.  A small proportion of asexual parasites convert to 
gametocytes that are critical for the transmission of the infection to other hosts through 
female anopheline mosquitoes.  This does not cause any disease.  
In this context, the strategy of P. vivax differs from that of P. falciparum.  P. 
vivax develops into gametocytes soon after release of merozoites from the liver while P. 
falciparum gametocytes develop much later.  Early treatment of clinical malaria by anti-
bloodstage chemotherapy for P. falciparum also kills the developing gametocytes; P. 
vivax transmits before the symptomatic stage of the disease (Weatherall et al., 2002). 
All the typical clinical symptomology and severe disease pathology associated 
with malaria is caused by the asexual erythrocytic or blood stage parasites (CDC, 2004). 
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The sequence of invasion into the red blood cells is probably similar for all Plasmodium 
species.  The merozoite first attaches to red cells. In P. falciparum, Erythrocyte Binding 
Antigen 175 and Merozoite Surface Protein 1, 2 with sialoglycoproteins have been 
identified as the ligands while in P. vivax, the Duffy antigen on RBC is the site of 
binding.  After the attachment to the red cell, the merozoite re-orientates itself so that 
apposition of apical end occurs.  This is followed by localized invagination and 
interiorization of the merozoite.  The entire process is completed in 30 seconds.  The 
growth and multiplication cycle within the RBCs (Erythrocytic schizogony) takes about 
48 hours for one cycle (72 hours in the case of P. malariae).  Each merozoite divides into 
8-32 (average 10) fresh merozoites.  The merozoites grow in stages into rings called 
trophozoites (trophos means nourish) and divide in a Schizont - meaning split - to release 
more merozoites (mero means separate).  At the end of this cycle, the mature schizonts 
rupture the RBCs and release the new merozoites into the blood, which in turn infect 
more RBCs.  The merozoite ingests hemoglobin from RBCs to form a food vacuole 
where it is degraded and heme is released.  The toxic heme is in turn detoxified by heme 
polymerase and sequestrated as hemozoin.  All the clinical features of malaria are caused 
by these events in the blood.  Eventually, the growing parasite progressively consumes 
and degrades intracellular proteins, principally hemoglobin, resulting in the formation of 
the 'malarial pigment' and hemolysis of the infected red cell.  This also alters the transport 
properties of the red cell membrane, and the red cell becomes more spherical and less 
deformable.  The rupture of red blood cells by merozoites releases certain factors and 
toxins, which could directly induce the release of cytokines such as TNF and interleukin-
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1 from macrophages, resulting in chills and high grade fever.  This occurs once in 48 
hours, corresponding to the erythrocytic cycle (Weatherall et al., 2002). 
Both P. falciparum and P. vivax can cause severe anemia, but only P. falciparum 
causes the multiple complications of cerebral malaria, hypoglycemia, metabolic acidosis, 
and respiratory distress.  Certain differences in the biology of the two parasites partially 
explain the differences in patterns of disease.  First, P. falciparum can invade a large 
percentage of the RBCs, whereas P. vivax is limited to reticulocytes.  A second difference 
between the two parasites is that there is a surprising redundancy of invasion pathways in 
P. falciparum. P. vivax invades only Duffy blood group-positive RBC23 and is largely 
limited to reticulocytes.  In West Africa, where the Duffy blood group is missing on 
RBCs, P. vivax essentially disappeared.  The limitations in invasion of P. vivax have led 
to the discovery of two families of parasite receptors: 1) the parasite molecule that binds 
to the Duffy blood group system and Duffy binding-like (DBL) homologous proteins of 
P. falciparum and P. knowlesi (Kappe et al., 1998) and 2) the parasite reticulocyte-
binding proteins of P. vivax (Galinski et al., 1992) and reticulocyte binding-like (RBL) 
homologous proteins of P. falciparum (Rayner et al., 2001).  The various members of the 
DBL and RBL families may recognize different RBC receptors than the Duffy blood 
group or the receptor on reticulocytes.  
 
Diagnosis 
 
 
The diagnosis of malaria involves identification of malaria parasite or its 
antigens/products in the blood of the patient.  Although this seems simple, the efficacy of 
the diagnosis is subject to many factors.  The different forms of the four malaria species, 
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the different stages of erythrocytic schizogony, the endemicity of different species, the 
population movements, the interrelation between the levels of transmission, immunity, 
parasitemia, and symptoms, the problems of recurrent malaria, drug resistance, persisting 
viable or non-viable parasitemia, and sequestration of the parasites in the deeper tissues 
all affect proper diagnosis.  Finally the use of chemoprophylaxis or even presumptive 
treatment on the basis of clinical diagnosis can all have a bearing on the identification 
and interpretation of malaria parasitemia on a diagnostic test (Malaria Site, 2006). 
Prompt and accurate diagnosis is the key to effective disease management, which 
is one of the main interventions of the Global Malaria Control Strategy (WHO, 1993).  It 
is thus of concern that poor diagnosis continues to hinder effective malaria control.  This 
is due to a combination of factors, including non-specific clinical presentation of the 
disease, high prevalence of asymptomatic infection in some areas, lack of resources and 
insufficient access to trained health care providers and health facilities, and widespread 
practice of self-treatment for clinically suspected malaria. 
The first and most practical method for diagnosing malaria is through clinical 
examination.  Clinical diagnosis is the most widely used approach in rural areas and at 
the periphery of the health care system where laboratory support to clinical diagnosis 
does not exist (WHO/USAID, 2000).  The problem with clinical diagnosis is that the 
symptoms of malaria are very non-specific, especially those of mild and moderate 
malaria.  A diagnosis of malaria based on clinical grounds alone is therefore unreliable.   
As a result, when malaria is suspected, the clinical examination should be followed by a 
microscopic diagnosis, which represents the established method for laboratory 
confirmation of malaria. In most settings, the procedure consists of collecting a finger-
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prick blood sample, preparing a thick blood smear (in some settings a thin smear is also 
prepared), staining the smear (most frequently with Giemsa), and examining the smear 
through a microscope (preferably with a 100X oil-immersion objective) for the presence 
of malaria parasites (Makler et al., 1998).  
 
Microscopy offers many advantages. 
 
- It is sensitive.  When used by skilled and careful technicians, microscopy can 
detect densities as low as 5 – 10 parasites per µl of blood (WHO, 1990).  Under 
general field conditions, however, the detection capabilities of a typical 
microscopist might be more realistically placed at 100 parasites per µl of blood 
(WHO, 1998).  
- It is informative.  When parasites are found, they can be characterized in terms of 
their species (P. falciparum, P. vivax, P. ovale, and/or P. malariae) and of the 
circulating stage (e.g. trophozoites, schizonts, gametocytes).  Occasionally, expert 
microscopists can detect morphological alterations induced by recent drug 
treatment.  In addition, the parasite densities can be quantified (from ratio of 
parasites per number of leukocytes or erythrocytes).  Such quantifications are 
needed to demonstrate hyperparasitemia (which may be associated with severe 
malaria) or to assess parasitological response to chemotherapy.  
- It is relatively inexpensive.  Cost estimates for endemic countries range from 
about US$ 0.12 to US$ 0.40 per slide examined (Palmer, 1999).  Such figures, 
however, do not reflect the true cost to the health system or to the patient, which 
may be substantially higher.  In addition, the cost per test will increase if 
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utilization is low, or if microscopy in the health facility is used only for malaria 
diagnosis.  
- It is a general diagnostic technique that can be shared with other disease control 
programs, such as those against tuberculosis or sexually transmitted diseases.  
- It can provide a permanent record (the smears) of the diagnostic findings and be 
subject to quality control.  
Microscopy suffers from three main disadvantages. 
- It is labor-intensive and time-consuming, normally requiring at least 60 minutes 
from specimen collection to result.  
- It is exacting and depends absolutely on good techniques, reagents, microscopes 
and, most importantly, well trained and well supervised technicians. 
Unfortunately these conditions are often not met, particularly at the more 
peripheral levels of the health care system.  
- There are often long delays in providing the microscopy results to the clinician, so 
that decisions on treatment are often taken without the benefit of the results. 
There are also non-microscopic tests that can be grouped in a category named ‘Rapid 
Diagnostic Tests’ (RDT).  These tests involve identification of the parasitic antigen or the 
anti-plasmodial antibodies, or the parasitic metabolic products.  Some of the most 
common RTDs are: OptiMal Assay, Polymerase Chain Reaction (PCR), the immune-
chromatographic test, the detection of antibodies by Radio-immuno assay, and 
immunofluorescence or enzyme immune assay. 
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The advantages of RDTs over microscopy are: 
 
 
- RDTs are simpler to perform and to interpret.  They do not require electricity, 
special equipment or training in microscopy.  Peripheral health workers (and other 
health providers as well as community volunteers) can be taught the procedure in 
a matter of hours, with good retention of skills over a one-year period.  
- RDTs are relatively robust and test performance and interpretation vary relatively 
little among individual users.  Moreover, most kits can be shipped and stored 
under ambient conditions.  
- Since RDTs detect circulating antigens, they may detect P. falciparum infection 
even when the parasites are sequestered in the deep vascular compartment and 
thus undetectable by microscopic examination of a peripheral blood smear.  In 
women with placental malaria (as demonstrated by placental smears), RDTs have 
detected circulating HRP-II even though the blood smears were negative due to 
sequestration of P. falciparum in the placenta (Leke et al., 1999). 
Disadvantages include: 
- Commercially available RDTs targeting HRP-II can detect only P. falciparum. 
Such kits will detect only a portion of cases in areas where other Plasmodium 
species are co-endemic.  They are not suitable for diagnosing cases of imported 
malaria from areas where P. falciparum is not necessarily the most prevalent 
species.  
- RDTs that target HRP-II of P. falciparum can give positive results for up to two 
weeks following chemotherapy and parasite clearance as confirmed by 
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microscopy.  The reason for this antigen persistence needs to be clarified. Pending 
such clarification, RDTs targeting HRP-II might yield confusing results in relation 
to the assessment of treatment failure or drug resistance.  
- The current RDTs are more expensive than microscopy, with costs per test 
varying from US$ 0.60 to US$ 2.50 and possibly more, depending on the 
marketing area.  
- RDTs are not quantitative.  They thus fail to provide information of possible 
prognostic importance and are not suitable for detailed investigations on the 
therapeutic efficacy of antimalarial drugs.  
- Kits that detect both P. facilparum and non-falciparum species cannot 
differentiate between P. vivax, P. ovale and P. malariae, nor can they distinguish 
pure P. falciparum infections from mixed infections that include P. falciparum.  
- RDTs that detect antigens produced by gametocytes can give positive results in 
infections where only gametocytes are present.  Gametocytes are not pathogenic, 
and gametocytes of P. falciparum can persist following chemotherapy without 
implying drug resistance.  Such positive RDT results can lead to erroneous 
interpretations (false positives) and unnecessary treatment of people not suffering 
from malaria. 
Now a differentiation has to be made between the diagnostic tools of choice in areas of 
high and low malaria transmission.  In high malaria endemicity areas, if a case is 
suspected of severe malaria, laboratory confirmation can guide initial therapy.  In 
facilities at the central and district levels, microscopy should be the confirmatory 
diagnostic test of choice.  In peripheral locations where microscopy is not available, 
36 
 
RDTs might prove particularly useful since they can be performed by health workers 
with limited training and skills.  Compared to blood smears, RDTs provide more timely 
results for disease management.  In low malaria endemicity areas, clinical diagnosis 
should be rapidly followed by microscopy and RDTs if necessary.  In the extreme case of 
remote communities or highly mobile populations, where microscopic diagnosis is not 
available and where patients do not have adequate access to health care facilities, 
treatment is frequently based on clinical diagnosis alone.  Here, the use of RDTs by local 
health workers or community volunteers has proved valuable.  
Another important factor to consider is the development of drug resistance.  In 
fact, when the diagnosis of malaria is based merely on a symptomatic evaluation, many 
problems can emerge.  First of all, since malaria has very unspecific symptoms, a 
diagnosis can never be accurate, and using malarial medicines when the agent causing the 
disease is not a parasite in the genus Plasmodium, greatly enhances the development of 
resistance.  Secondly, resistance to available drugs in many areas of the world is an 
emerging problem, it is species specific and it has a geographical distribution; therefore 
prescribing a certain medicine ignoring what Plasmodium species is causing the 
infection, can strengthen their resistance and expand the problem.  A series of wrong 
diagnosis has certainly played a role in the development of drug resistance worldwide, 
especially to the two traditional medicines that have represented first- or second-line 
treatment for many decades: chloroquine and sulfadoxine–pyrimethamine.  This has lead 
to the need of developing new antimalarial drugs; today public health authorities, in order 
to avoid an increase in the resistance to the traditional medicines, recommend the use of a 
fairly new group of drugs to which all Plasmodium species have shown susceptibility: 
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artemisinin and its derivatives.  The downside of artemisinin is its relatively high cost and 
lower safety. 
 
Treatment 
 
 
The development of resistance to the available drugs in the last few decades has 
posed a serious challenge in our goal of achieving malaria eradication and has evolved 
our way of facing and managing the disease.  It is undoubtedly a complicated problem.   
Until a few decades ago, chloroquine was a very effective medicine and no signs of 
resistance had yet appeared.  Then, the indiscriminate use of chloroquine posed a very 
heavy selective pressure on the parasite and this process slowly lead to the insurgence of 
resistant strains that survived the action of the drug.  As time went by, resistant strains 
were effectively reproducing and allowed for a successful transmission; this created a 
worldwide resistance of P. falciparum to most of the available medicines, such as 
amodiaquine, chloroquine, mefloquine, quinine, and sulfadoxine-pyrimethamine.  As we 
know, P. falciparum is the most prevalent and dangerous malarial parasite, hence, in this 
discussion, we will mainly focus on the treatment of this form of malign malaria.  
There is a series of factors that allowed the parasite to develop resistance.  Some 
of these factors are: the extremely high prevalence of the disease throughout the world, 
the administration of drugs when malaria was only suspected through clinical symptoms 
(and the patient was malaria negative), the poor adherence to the recommended therapy, 
the prescription of ineffective drugs against a specific species of parasite, and the use of 
monotherapy (single drug against the parasite) as opposed to combination therapy, in 
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which two different drugs have  two distinct modes of action on the parasite (Hastings & 
Mackinnon, 1998). 
Resistance to antimalarials has been documented for P. falciparum, P. vivax, and, 
recently, P. malariae. In P. falciparum, resistance has been observed to almost all 
currently used antimalarials (amodiaquine, chloroquine, mefloquine, quinine and 
sulfadoxine–pyrimethamine) except for artemisinin and its derivatives.  The geographical 
distribution and rates of diffusion have varied considerably. P. vivax has rapidly 
developed resistance to sulfadoxine–pyrimethamine in many areas.  Chloroquine 
resistance is confined largely to Indonesia, East Timor, Papua New Guinea and other 
parts of Oceania.  There are also documented reports from Peru. P. vivax remains 
sensitive to chloroquine in South-East Asia, the Indian subcontinent, the Korean 
peninsula, the Middle East, North-East Africa, and most of South and Central America 
(WHO, 2006).  
As it can easily be extrapolated, treatment of malaria today is a very complex 
topic.  First, a number of general properties of the current antimalarial drugs will be 
delineated; this will be followed by an in-depth discussion of the specific medicines 
against different parasites and their different types of combination, settings, and 
interventions.  Generally speaking, antimalarials can help bring about a reduction in 
malaria transmission by their effect on parasite infectivity.  This can be a direct effect on 
the gametocytes, the infective stages found in human infections (gametocytocidal effect) 
or, when the drug is taken up in the blood meal of the mosquito, an effect on the 
parasite’s development in the insect (sporonticidal effect).  Chloroquine (CQ) acts against 
young gametocytes but has no suppressive effects on mature infective forms (Bruce-
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Chwatt, 1981).  Chloroquine has even been shown to be capable of enhancing the 
infectivity of gametocytes to the mosquito (Hogh et al., 1998).  In contrast, sulfadoxine-
pyrimethamine (SP) increases gametocyte carriage but, provided there is no resistance, 
reduces the infectivity of gametocytes to mosquitoes (Hogh et al., 1998; Robert et al., 
2000; von Seidlein et al., 2001).  Artemisinins are the most potent gametocytocidal drugs 
among those currently being used to treat an asexual blood infection (von Seidlein et al., 
1998; Targett et al., 2001; Drakeley et al., 2004).  They destroy immature gametocytes, 
preventing new infective gametocytes from entering the circulation, but their effects on 
mature gametocytes are less, hence they will not affect the infectivity of those already 
present in the circulation at the time a patient presents for treatment (Pukrittayakamee et 
al., 2004).  Primaquine, an 8-aminoquinoline antimalarial that has been widely used as a 
hypnozoiticidal drug, is the only antimalarial medicine that had been deployed in the 
treatment of P. falciparum infections due to its effects on infectivity.  It acts on mature 
infective gametocytes in the circulation and accelerates gametocyte clearance 
(Pukrittayakamee et al., 2004), as opposed to artemisinins, which mainly inhibit 
gametocyte development.  Amodiaquine is an antimalarial with schizonticidal activity.  It 
is effective against the erythrocytic stages of all four species of Plasmodium falciparum.   
It is as effective as chloroquine against chloroquine-sensitive strains of Plasmodium 
falciparum and it is also effective against some chloroquine-resistant strains.   
Amodiaquine accumulates in the lysosomes and brings about loss of function.  The 
parasite is unable to digest hemoglobin on which it depends for its energy (‘Crusade 
Against Malaria’, 2008).  Lastly, mefloquine is indicated for the treatment of mild to 
moderate acute malaria caused by mefloquine-susceptible strains of P. falciparum (both 
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chloroquine-susceptible and resistant strains) or by Plasmodium vivax.  There are 
insufficient clinical data to document the effect of mefloquine in malaria caused by P. 
ovale or P. malariae.  Patients with acute P. vivax malaria, treated with mefloquine, are at 
high risk of relapse because mefloquine does not eliminate exoerythrocytic (hepatic 
phase) parasites (RxList, 2008). 
 
 
 
Table 5: Effects of Some Commonly Used Antimalarials on the Infectivity of P. 
falciparum to the Mosquito.  (WHO, 2006) 
 
  
Treatment of Uncomplicated P. falciparum Malaria 
 
 
 Today the World Health Organization recommends combination therapy for the 
treatment of falciparum malaria.  Monotherapy is strongly discouraged as either 
resistance is already present or it may lead to the process of resistance development.  The 
parasites that survive have genes that make them resistant to a certain drug and these 
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same genes can then be transmitted to the mosquito when it bites and, consequently, to 
humans (Hallett et al., 2004). 
Antimalarial combination therapy is the simultaneous use of two or more blood 
schizontocidal drugs with independent modes of action and thus unrelated biochemical 
targets in the parasite.  The concept is based on the potential of two or more 
simultaneously administered schizontocidal drugs with independent modes of action to 
improve therapeutic efficacy and also to delay the development of resistance to the 
individual components of the combination (WHO, 2006). 
The recommended treatment for the cure of falciparum malaria is the 
Artemisinin-based Combination Therapy (ACT).  There are four derivatives of 
artemisinin that induce a rapid clearance of parasitemia and a resolution of the symptoms.   
They reduce the parasite number by a factor of approximately 10000 in each asexual 
cycle, which is more than other current antimalarials (100- to 1000-fold per cycle).   
Artemisinin and its derivatives are also rapidly eliminated.  When given in combination 
with rapidly eliminated compounds (tetracyclines, clindamycin), a 7-day course of 
treatment with an artemisinin compound is required; but when given in combination with 
slowly eliminated antimalarials, shorter courses of treatment (3 days) are effective.  A 
trial that compared the effects of a single drug such as amodiaquine, mefloquine, or 
sulfadoxine-pyrimethamine with that of one of those same drugs with the addition of 
artesunate (an artemisinin derivative), found that there was a clear benefit in the use of 
the combination treatment.  It also resulted in fewer parasitological failures at day 28 
which is the current recommended duration of follow-up.  This is when the treatment is 
considered to be successful, even though recrudescence may occur and another cycle 
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needs to be begun with the same firs-line treatment or, if the circumstances suggest that 
sensitivity is not sufficient, then the second-line treatment may be used.  Another 
characteristic that make artemisinin compounds ideal for the treatment of malaria is that 
they are active against all four species of malaria parasites and are generally well 
tolerated.  As previously mentioned, these drugs also have the advantage, from a public 
health perspective, of reducing gametocyte carriage and thus the transmissibility of 
malaria.  This contributes to malaria control in areas of low endemicity (WHO, 2006).  
As mentioned, the concept of ACT is based on the use of an artemisinin 
derivative and the choice of another drug.  Whereas no significant differences in the 
efficacy of the artemisinin product in terms of absorption and bioavailability have been 
demonstrated, it is the properties of the partner medicine that determines the effectiveness 
and choice of combination.  Various combination therapies have been evaluated in 
multiple clinical trials where an artemisinin compound was given in conjunction with 
another drug such as amodiaquine, chloroquine, lumefantrine, mefloquine, piperaquine, 
and doxycycline.  The combinations that proved to be the most advantageous were (in 
alphabetical order):  
- artemether-lumefantrine 
 
- artesunate + amodiaquine 
 
- artesunate + mefloquine 
 
- artesunate + sulfadoxine-pyrimethamine 
 
Although for many countries, artemether-lumefantrine and artesunate + 
mefloquine may give the highest cure rates, there may be problems of affordability and 
availability of these products.  Also, there is currently insufficient safety and tolerability 
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data on artesunate + mefloquine at the recommended dose of 25mg/kg in African 
children to support its recommendation there.  Trials with mefloquine monotherapy 
(25mg/kg) have raised concerns of tolerability in African children.  Countries may 
therefore opt to use artesunate + amodiaquine and artesunate + sulfadoxine–
pyrimethamine, although they may have lower cure rates because of resistance (WHO, 
2006). 
 Finally, a last note on a crucial aspect of malaria treatment: treatment 
management. In order to optimize the benefit of deploying ACTs, and to have an impact 
on malaria, it will be necessary to deploy them as widely as possible; this means that they 
will have to reach the most peripheral health centers and communities.  The 
dissemination of clear national treatment guidelines, use of appropriate information, 
education, communication materials, monitoring of the deployment process, access and 
coverage, and the provision of adequately packaged antimalarials are needed to optimize 
the benefits of providing these new effective treatments (WHO, 2006). 
 
Treatment of Malaria Caused by P. vivax, P. ovale, and P. malariae 
 
 
P. vivax has been characterized thoroughly in terms of pharmaceutical sensitivity 
and resistance due to its high prevalence in endemic areas of the Middle East, Oceania, 
and Central and South America.  In Africa, it is rare except in the Horn and it is almost 
absent in West Africa.  In most areas where P. vivax is prevalent, malaria transmission 
rates are low, and the affected populations therefore achieve little immunity to this 
parasite.  Consequently, people of all ages are at risk.  
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The other two human malaria parasite species, P. malariae and P. ovale, are 
generally less prevalent but are distributed worldwide, especially in the tropical areas of 
Africa. 
 Of these three parasites, only P. vivax and P. ovale form hypnozoites, the liver 
stage of the parasite that can result in relapses of infection.  This affects the development 
and schooling of children and debilitates adults, thereby impairing human and economic 
development in affected populations.  Therefore, when treating these two forms of 
malaria, the goal is to cure both the blood stage and the liver stage infections, thereby 
preventing both relapses and recrudescence.  This is known as radical cure.  
 Recent data on the in vivo susceptibility of P. ovale and P. malariae are very few.   
Both are regarded as very sensitive to chloroquine, although there is a single recent report 
of chloroquine resistance in P. malariae.  They are also thought to be susceptible to 
amodiaquine, mefloquine, and the artemisinin products.  On the other hand, P. vivax has 
received much more attention and therefore we possess very extensive studies that assess 
the susceptibility to drugs of this parasite.  It is still generally very sensitive to 
chloroquine, although resistance has emerged in some areas such as Oceania, Indonesia, 
and Peru. Resistance to pyrimethamine has increased rapidly in some areas, and 
sulfadoxine-pyrimethamine is consequently ineffective.   In general, P. vivax is sensitive 
to all the other antimalarial drugs; it is more sensitive than P. falciparum to the 
artemisinin derivatives, and slightly less sensitive to mefloquine (although mefloquine is 
still effective).  The only drugs with significant activity against the hypnozoites are the 8-
aminoquinolines.  
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 As far as P. ovale is concerned, the recommended treatment for the relapsing 
malaria is the same as that given for radical cure in P. vivax, i.e. with chloroquine and 
primaquine.  Instead, P. malariae should be treated with the standard regimen of 
chloroquine as for vivax malaria, but it does not require radical cure with primaquine as 
no hypnozoites are formed in infection with this species. 
 
Malaria and Plasmodium falciparum 
 
 
Epidemiology 
 
 
First of all, it is important to consider that there are three main factors that determine 
the occurrence of malaria.  These factors also correspond to the three components of the 
malaria cycle: 
1. In order for the parasite to complete the "invertebrate host" half of their life cycle, 
Anopheles mosquitoes must be present and must be in contact with humans. 
2. In order for the parasites to complete the "vertebrate host" half of their life cycle, 
humans must be present and must be in contact with Anopheles mosquitoes.  
3. Malaria parasites must be present (CDC, 2004). 
Climate can also influence all three components of the life cycle.  It is thus a key 
determinant in the geographic distribution and the seasonality of malaria.  An essential 
resource for the successfull reproduction and development of the mosquito eggs is the 
presence of water.  The required time for the eggs to develop into larvae, pupae, and 
adults, is approximately 9-12 days in tropical areas.  In case rain is scarce and water dries 
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up too quickly, the egg is not able to complete its evolution; on the other hand, when 
rains are too excessive, eggs are can be damaged and flushed away.  
Once adult mosquitoes have emerged, the ambient temperature, humidity, and 
rains will determine their chances of survival.  Once an adult mosquito takes a bite on an 
infected human, the parasite needs to go through a whole new growth cycle inside the 
mosquito, known as the extrinsic cycle.  This cycle takes about 9 to 21 days to complete 
at 25°C, meaning that the mosquito needs to survive long enough to allow the extrinsic 
cycle to complete.  Warmer climates shorten the extrinsic cycle, thus increasing the 
chances of transmission.  Conversely, below a certain temperature (15°C for Plasmodium 
vivax, 20°C for P. falciparum), the extrinsic cycle cannot be completed and malaria 
cannot be transmitted (Craig et al., 1999). 
 
Epidemiological Patterns, Transmission, and Distribution 
 
There is a fundamental concept that describes and influences the epidemiology 
and distribution of malaria: transmission.  Transmission is described in terms of intensity, 
stability, and seasonal patterns.  The intensity of transmission can be measured as the 
average number of infectious bites received during a given period of time by an 
individual living in the area.  Stability regards the situation over a period of years.  In 
areas of stable transmission, the pattern of transmission remains roughly unchanged from 
year to year, whereas areas with unstable malaria are characterized by considerable 
variation in the intensity of transmission between years.  In areas of stable malaria 
transmission, the transmission intensity is roughly reflected in the spleen rates and the 
point prevalence of parasitemia in children (Gilles, 1993).   
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According to the levels of spleen rate and parasitemia, endemicity is comprised of 
four categories: holoendemic, hyperendemic, mesoendemic, and hypoendemic.  In 
holoendemic area, transmission occurs all year long.   In hyperendemic areas, 
transmission is intense but with periods of no transmission during the dry season.  In 
mesoendemic regions, there is a regular seasonal transmission.  Finally, in hypoendemic 
areas, transmission is very intermittent (Shiff, 2006).  Table 6 summarizes the 
characteristics of the four different levels of endemicity. 
 
 
Spleen 
rate*in < 5 
year old 
Parasitemia 
<5 year old Transmission 
Clinical 
Manifestations Mortality 
Holoendemic > 75% 60 – 70 % Stable** Anemia severe in 
early life 
High in 
1st and 
2nd year 
of life 
Hyperendemic 50 – 70 % 50 – 70 % Seasonal but intense. Stable 
Cerebral malaria in 
older children  
Mesoendemic 20 – 50 % < 20% Seasonal. Unstable*** 
Cerebral malaria 
common 
 
Hypoendemic 0 – 10 % 0 – 10 % 
Periodic/Unusu
al rainfall. 
Unstable 
Severe outbreaks in 
children/adults 
High in all 
groups 
and ages 
Table 6: Levels of Endemicity of Malaria and Associated Statistics and 
Characteristics.  (Shiff, 2006) 
 
* Spleen Rate: number of palpable enlarged spleens per 100 individuals of similar ages. 
 
** Stable malaria occurs in areas of high prevalence, cases are frequently asymptomatic, 
fever occurence is infrequent, anemia is high at younger ages (particularly under 2 years 
of age), and mortality is greatest under 2 years of age (Shiff, 2006).  
*** Unstable malaria is based on immunity achieved through personal exposure to 
Plasmodium antigens.  Since exposure in areas of low endemicity is usually low, the 
immune system is naive to the antigens and is not able to effectively produce a strong 
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immune response; a broad range of disease situations is possible, including cerebral 
malaria in children 4 – 6 years old and adult malaria.  Since the infection is highly 
symptomatic, a rapid diagnosis is critical and prompt effective treatment is vital to avoid 
fatalities (Shiff, 2006). 
Now why do children over five years of age and adults living in areas of stable 
malaria transmission are immune to malaria?  It has been proven that individuals develop 
immunity to the malarial parasites through repeated exposure all year round and over the 
years.  In this type of settings, children over the age of five and adults are progressively 
more immune to malaria because they have been exposed to the parasite for a prolonged 
and constant period of time.  Those living in an area of low transmission setting should 
progress to clinical disease and severe manifestations and the age is a less determining 
factor since no one is constantly exposed to the parasite over the course of the his life 
(Reyburn et al., 2005).  In fact, recent studies in Tanzania and Kenya have highlighted 
the fact that the epidemiology and clinical manifestations of severe malaria vary with the 
intensity of transmission (Snow et al., 1994).  Theoretically, individuals living in an area 
of low transmission should suffer from complicated disease but this is not always the 
case.  A study conducted in Daraweesh, Sudan, an area of low and unstable transmission 
where the season of heavy rain is followed by the dry season, found that local dwellers 
did acquire the ability to control some infection.  However, the protection is far from 
solid and malaria occurs in all age-groups, although the risk of getting malaria decreases 
with age (Theander, 1998). 
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Geographical Distribution 
 
 
Figure 7: Geographical Distribution of Malaria.  (WHO 2006) 
 The distribution of malaria depends mainly on climatic factors such as 
temperature, humidity, and rainfalls (CDC, 2004).  As mentioned early, in tropical and 
subtropical areas two factors are needed for the transmission of malaria to be successful:  
I) Anopheles mosquitoes can survive and multiply and II) Malaria parasites can complete 
their growth cycle in the mosquitoes (extrinsic incubation period). 
 There are also some geographical features that prevent the transmission from 
occurring: 
- high altitudes  
- cooler seasons in some areas  
- deserts (excluding the oases)  
- some islands in the Pacific Ocean which have no local Anopheles species   
capable of transmitting malaria 
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The highest transmission is found in Africa south of the Sahara, where the 
closeness to the equator makes the climate warmer; in these conditions, transmission is 
more intense, malaria is transmitted year-round, and P. falciparum predominates.  
In cooler regions, transmission will be less intense and more seasonal.  There, P. 
vivax might be more prevalent because it is more tolerant of lower temperatures.  
 
Drug Resistance 
 
 
The World Health Organization defines antimalarial drug resistance as the ability 
of a parasite strain to survive and/or multiply despite the administration and absorption of 
a drug given in doses equal to or higher than those usually recommended but within 
tolerance of the subject (WHO, 2001).  This definition was later modified to specify that 
the drug in question must gain access to the parasite or the infected red blood cell for the 
duration of the time necessary for its normal action (Bruce-Chwatt et al., 1986).  The first 
scientific reviews in the literature that discussed the emerging problem of drug resistance 
appeared in the mid ‘80s and reported that Plasmodium falciparum in Central and West 
Africa was becoming resistant not only to chloroquine, but also to all existing alternative 
treatments except quinine (Ambroise-Thomas & Rossignol, 1986).  Today, drug 
resistance varies largely depending on the geographic region, the drug being used, and 
the different species of the Plasmodium parasite.  In P. falciparum, resistance has been 
observed to almost all currently used antimalarials (amodiaquine, chloroquine, 
mefloquine, quinine and sulfadoxine–pyrimethamine) except for artemisinin and its 
derivatives.  The geographical distributions and rates of diffusion have varied 
considerably. P. vivax has developed resistance rapidly to sulfadoxine–pyrimethamine in 
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many areas.  Chloroquine resistance is confined largely to Indonesia, East Timor, Papua 
New Guinea and other parts of Oceania though there are also documented reports from 
Peru.  P. vivax remains sensitive to chloroquine in South-East Asia, the Indian 
subcontinent, the Korean peninsula, the Middle East, north-east Africa, and most of 
South and Central America (Table 7 & Fig. 8) (WHO, 2006). 
 
Table 7: Distribution of Drug-Resistant P. falciparum Malaria.  (WHO, 2001) 
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Figure 8: Malaria Transmission Areas and Reported Drug Resistance. (WHO, 2004) 
 
A number of factors that are thought to contribute to the development and 
intensification of drug resistance have been identified.  These are: incorrect dosing, non-
compliance with duration of dosing regimen, poor drug quality, drug interactions, poor or 
erratic absorption, and misdiagnosis (WHO, 2001). 
In terms of the molecular processes that lead to the formation of resistance, there 
are a number of mechanisms that characterize each category of drugs.  
- Chloroquine has the capacity of capture harmful heme moieties which are 
produced by the parasites as a by-product of hemoglobin digestion, its major 
source of amino acids.  This process occurs in digestive vacuoles in which 
choloroquine can exert its function if the parasite is chloroquine sensitive, 
otherwise, if the parasites are choloroquine resistant, this drug will not be able to 
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accumulate at sufficient levels that will allow it to play its role of eliminating 
heme moieties.  The different behavior is due to mutations in the pfcrt 
(Plasmodium falciparum chloroquine resistance transporter) gene; resistant strains 
of the parasite have several nucleotide substitutions due to the great variety of 
chloroquine resistant parasites, but one amino acid is found constantly in resistant 
strains, K76T (Hyde, 2007).  These mutations are thought to play a role in 
determining the characteristics of CRT (chloroquine resistance transporter) with 
respect to the drugs; scientists suggest that the K76T amino acid alters the activity 
of the CRT in a way that chloroquine exits the vacuole more rapidly (Johnson et 
al., 2004).  One possible explanation for this modification is that when K76 is 
present, the expulsion of drug outside the vacuole through CRT is limited due to 
the amino acid positive charge; when the strain is resistant and K76T comes into 
action, the movement of chloroquine towards the outside of the vacuole is 
excessive and accelerated (Hyde, 2007).    
- Another category of drugs that is worth mentioning are the antifolates.  The 
principal drugs of interest within this class are pyrimethamine and sulfadoxine.   
Pyrimethamine targets the dihydrofolate reductase (DHFR) activity of the DHFR-
thymidylate synthetase protein, while sulfadoxine inhibits the dihydropteroate 
synthetase (DHPS) activity of the DHPS-hydroxymethylpterin 
pyrophosphokinase.  DHFR enzyme is present in both the host and the parasite 
and its role pertains the constant supply of fully reduced forms of folate 
conenzymes that help, for instance, in the provision of nucleotides for DNA 
synthesis and the metabolism of certain amino acids.  DHPS is only found in the 
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parasite and it is also used in the biosynthesis of essential folate enzymes.  These 
drugs bind to these two enzymes several hundred times more strongly in the 
parasite than in the human orthologue, therefore effectively exerting its action on 
the parasite and not affecting the functions of the enzyme in humans in the case of 
DHFR.  The genetic basis of resistance to the antifolate drugs is similar to that 
underlying chloroquine resistance, in that a small number of point mutations in 
these two target genes appear to be responsible for the major part of resistance 
(Hyde, 2007).  
- Finally artemisinin is thought to function, upon activation by Fe2+, by inhibiting 
the Ca2+ sarco/endoplasmic reticulum calcium-dependent ATPase (SERCA) 
PfATPase6, a transporter found on membranous structures within the parasite 
cytoplasm (Hyde, 2007).  Resistance to artemisinin products has not quite 
emerged yet, primarily due to its use in combination therapy, even though in vitro 
resistance has been reported in isolates from French Guiana, Cambodia, and 
Senegal.  In a study conducted by Jambou and collegues, the coding sequences of 
PfATPase6 isolates from these three countries were established and substantial 
polymorphism was observed, especially in the Cambodian strains.  More 
specifically, the polymorphism of S769N, found in many of the isolates, was 
associated with an increased mean IC50 (measure of the effectiveness of a 
compound in inhibiting biological or biochemical function) for arthemeter 
(Jambou et al., 2005).  In fact, for instance, the S769N mutation differs from the 
engineered L263E replacement, which eliminates artemisinin inhibition of the 
PfATPase6 enzymatic activity (Uhlemann et al., 2005).  In certain species, 
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residue 769 is essential to the structural transitions needed for the progress of the 
ATPase cycle and calcium binding and release.  By analogy with the inhibition of 
the rabbit SERCA by thapsigargin, a structural analogue of artemisinins, it is 
inferred that the S769N mutation prevents artemisinin derivatives from interfering 
with these conformational changes (Jambou et al., 2005). 
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Table 8: P. falciparum Proteins with a Proven Role in Resistance to Clinical 
Antimalarial Drugs.  (Jambou et al., 2007) 
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Cytochrome b5 Reductase (cb5r) and Cytochrome b5 (cb5) 
 
Cytochrome b5 Reductase 
 
 
Cytochrome b5 reductase (cb5r) is a member of the FNR superfamily of 
flavoprotein oxidoreductases and contains a single flavin adenine dinucleotide (FAD) 
group (Shirabe et al., 1997).  The function of this enzyme is to catalyze the transfer of 
two electrons from NADH to two molecules of cytochrome b5 in one catalytic cycle 
(Strittmatter, 1965).  
 Cb5r exists in two forms, a membrane-bound form that is comprised of both a 
hydrophobic membrane-anchoring region (Mr ~ 3 kDa, residues 1-25) and a hydrophilic, 
catalytic portion (Mr ~ 30 kDa, residues 26-300), and a soluble form comprising only the 
soluble reductase.  The soluble form of cb5r exists in circulating erythrocytes and 
participates in methemoglobin reduction, while the membrane-bound form is embedded 
in the membranes of the somatic cells such as those of the endoplasmic reticulum, 
mitochondria, and plasma membrane (Bewley et al., 2001).  
For the purpose of this project, the membrane-bound form of cb5r will have 
greater importance and will represent the predominant topic.  As mentioned, membrane-
bound cb5r consists of a hydrophobic N-terminal membrane-anchoring domain, and a 
larger hydrophilic, soluble catalytic domain.  It contains four conserved motifs: two 
NADH binding motifs, a flavin-binding motif, and a FMN/FAD selectivity motif 
(Marohnic et al., 2005).  
A well known cb5r protein structure is represented by the rat cb5r.  The structure 
has a typical two-domain arrangement, with an amino-terminal binding domain (residues 
33-147) and a carboxyl-terminal NADH-binding domain (residues 171-300).  These two 
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domains are linked by a 25-amino acid, three-stranded antiparallel β-sheet (residues 148-
170) that is thought to serve as a hinge to orient the NADH and FAD-binding domains, 
so that an efficient transfer of electrons from NADH to flavin can occur.  There is also an 
FAD molecule that interacts with both domains through hydrogen bonds (Fig. 9b).  The 
FAD-binding domain is a six-stranded, antiparallel β-barrel with a ~ 30˚ twist of each 
strand. The barrel is capped by the only α-helix in this domain.  A long loop (residues 
110-125), located between strand 5 and the α-helix, forms a lid that contributes to the 
majority of interactions of the FAD-binding domain with the adenine dinucleotide moiety 
of the FAD.  The NADH-binding domain contains a typical Rossman fold (three α/β/α 
layers that pack into a five-stranded parallel β-sheet in the order 3, 2, 1, 4, 5) (Fig. 9a) 
(Bewley et al., 2001); these folds are able to bind only one nucleotide at a time, thus in 
this case there are two paired Rossman folds that bind to the incoming NADH molecule 
(Rao & Rossman, 1973). 
   
 
Figure 9: Structure of Rat Cb5r. (Bewley et al., 2001) 
(a) Stereo ribbon diagram of rat cb5r. The FAD-binding domain is colored red, the NADH-binding domain 
is blue, the three-stranded linker domain is green, and the FAD molecule is shown in a ball and stick 
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representation using standard atom colors. (b) Interactions of the FAD and visible region of the NAD. 
Water-mediated hydrogen bonds are shown as cyan dotted lines. 
 
 
Cytochrome b5 
 
 
Cytochrome b5 (cb5) is an electron transfer protein with a redox potential of 20 
mV which is capable of accepting and transferring a single electron (Velick & 
Strittmatter, 1956).  It is a small protein of about 17 kDa found throughout the phyla, 
from yeasts to insects, seed plants and animals.  In all species and tissues (except 
erythrocytes), it is anchored in the membranes by a hydrophobic, carboxyl-terminal end 
of the peptide chain.  In erythrocytes, a truncated, soluble form of the protein is found 
(Schenkman & Jansson, 1999).  The protein has a heme prosthetic group that lacks a free 
coordination position and consequently, it serves as a physiological electron transfer 
component facilitating a number of reactions, including fatty acid desaturation, fatty acid 
elongation, and cytochrome P450 (P450) monooxygenation (which in turn is involved in 
the catabolism of xenobiotics) (Schenkman & Jansson, 1999; Keyes et al., 1979; Conney 
et al., 1957).  
 Structurally, cb5 is a small, cylindrical, acidic membrane protein consisting of 6 
helices and 5 β-strands. The protein is folded into two domains, the larger of which is the 
cytosolic heme-containing, amino-terminal, hydrophilic region.  The smaller domain is 
the hydrophobic, membrane-binding carboxyl portion of 14–18 residues, connected to the 
globular domain by a proline-containing hinge region of ~7 amino acids, and followed by 
7 polar amino acids at the very end of the polypeptide chain (Fig. 10) (Mathews, 1985).   
Proteases can clip before or after the proline-containing hinge region, releasing the 
soluble, catalytic heme-containing domain.  In mammals, 23 of the 134 amino acids are 
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either glutamate or aspartate and are completely conserved.  Most of them are located in 
the hydrophilic region of the protein.  The heme is located in a hydrophobic pocket, and 
the heme iron is coordinated with two completely conserved histidine side chains, H68 
and H44.  This binding prevents direct interaction of cb5 with molecular oxygen 
(Schenkman & Jansson, 2003).  
 Another important characteristic of cb5 is its site of biosynthesis and subsequent 
association with the membrane of the organelles in which they are embedded.  It has been 
shown that cb5 and its reductase cb5r are synthesized in free polysomes and therefore, 
their association with the membrane must be established post-translationally, as opposed 
to the case of another reductase, P450, which plays a variety of roles in conjunction with 
cb5 and cb5r.  P450 is synthesized in bound polysomes and cotranslationally inserted into 
the endoplasmic reticulum membranes (Okada et al., 1981).  
 
 
Figure 10: Cytochrome b5 Diagram. (Ramamoorthy, 2009) 
This figure shows the hydrophobic portion imbedded in the phospholipid bilayer of the membrane and the 
larger hydrophilic segment that lays in the cytosol. 
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Cb5r and Cb5 Function 
 
 
Cb5r and cb5 work in an interrelated fashion and depend on each other for the 
exchange and flow of electrons.  More specifically, cb5r catalyzes the transfer of two 
electrons from NADH to two molecules of cb5 in one catalytic cycle (Shirabe et al., 
1997).  When these two proteins are found in the soluble form in erythrocytes, the 
electrons donated to cb5 are used to reduce the ferric heme iron of hemoglobin to the 
ferrous state, resulting in the formation of methemoglobin (Hultquist & Passon, 1971).   
The membrane-bound forms on the other hand, serve a different function, participating in 
the elongation and desaturation of fatty acids, cholesterol biosynthesis, and some of 
cytochrome P450 mediated dug metabolism (Schenkman & Jansson, 1999; Keyes et al., 
1979; Conney et al., 1957).  Physiological electron donor of cb5 is NADH-cytochrome b5 
reductase and acceptors are methemoglobin, fatty acid desaturase, and cytochrome P450 
(Shirabe et al., 1997).  
 In fatty acid desaturation, cb5 participates in the synthesis of unsaturated fatty 
acids by donating electrons, which it receives from NADH-cb5r, to desaturases which are 
microsomal, non-heme, iron-containing proteins.  The desaturases use the electrons from 
cb5 to generate an electron-deficient, activated oxygen species which removes electrons 
from the saturated hydrocarbon.  Unsaturated fatty acids possess a structural role in 
cellular membranes where they greatly contribute to the fluidity of the cellular 
membranes.  They are also precursors of polyunsaturated fatty acids which are important 
mediators and regulators of various cell functions (Vergeres & Waskell, 1995). 
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 In cholesterol biosynthesis, cb5 has been shown to provide the reducing 
equivalents to the 19-step microsomal conversion of lanosterol to cholesterol; more 
precisely, it supplies electrons in the reaction in which 4-methyl sterol oxidase (a 
desaturase) oxidizes the C-30 methyl group of lanosterol (the cholesterol precursor) to a 
steroid acid which can be consequently decarboxylated (Fukushima et al., 1981). 
 The role and mechanism of action of cb5r and cb5 in drug metabolism is still 
subject of much research; many studies link the involvement of cb5r and cb5 in 
cytochrome P450-mediated reactions, which include drug metabolism (Porter, 2002).  
The interests are concentrated on the possibility of an NADH-cb5 driven, P450 reductase 
independent pathway of drug metabolism (Yamazaky et al., 1996).  In particular, the 
cb5r/cb5 action is thought to be involved in the donation of the second of the two required 
electrons for the reduction of P450 in the catalytic cycle (Pompon & Coon, 1984).  The 
complete process and set of reactions will be explained in the next section. 
 
Cb5r and Cb5 Relationship and Interaction 
 
 
 The link between cb5r and cb5 comes from the knowledge that there exist a 
transfer of electrons and a consequent electrostatic interaction between the reductase and 
the hemoprotein (Shirabe et al., 1997).  There are propionate groups of the heme in cb5, 
which are thought to be an electron pathway to heme iron from cb5r, that protrude from 
the molecular surface.  All charged residues around this heme-protruding site are 
negative (Mathews et al., 1971).  These negatively charged residues are very numerous 
and are able to form several hydrogen bond pairs with positively charged residues on the 
flavin protruding site of cb5r.  The actual interaction occurs between some carboxyl 
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residues of cb5 have been proven to be involved in the charge-pairing with the lysil 
residues of cb5r (Strittmatter et al., 1992).  In the same study, it was found that lysil 
residues around the flavin-protruding site of cb5r are implicated in the formation of 
charge pairs with carboxylate residues of cb5.  The specific links are found between 
Lys13 and Glu48 (or Glu 56), Lys 97 and Glu43 (or Glu44), and Lys134 and the heme 
propionate; in all three pairs, the former residue is of cb5r and the latter is of cb5.  
 In figure 11, a docking model of cb5r and cb5, the positively charged residues 
around the flavin of cb5r are involved in hydrogen bonding with cb5.  Here, Lys 97 and 
Lys134 of cb5r and Glu44 and propionate of cb5 form two hydrogen-bonded pairs. 
However, Lys13 and Glu48 or Glu56 are separated.  All three hydrogen-bonded pairs 
(Lys13/Glu48, Lys 97/Glu43, and Lys134/propionate) cannot be formed simultaneously 
in a single docking form like this one because the three residues of each of the two 
molecules are arranged counterclockwise when viewed from the exterior (Nishida & 
Miki, 1996). 
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Figure 11: Ribbon Diagram of the Docking Model of Pig Cb5r and Cb5. (Nishida & 
Miki, 1996) 
The molecules of cb5r (left) and cb5 (right) are represented by yellow and brown, respectively. The residues 
whose side chains are involved in hydrogen bonds between the molecules are represented by stick model 
and colored by their charge, cyan (positive), red (negative), and white (neutral). The atoms involved in the 
hydrogen bonds are represented by balls. 
 
Another consideration to be made is that cb5 also interacts with the NADH-
binding domain of cb5r through the formation of four salt bridges.  There is evidence 
through a study on transient kinetics, that the binding of NADH modulates the formation 
of the cb5r/cb5 complex.  It is also thought that these two NADH and FAD domains are 
tightly packed under NADH-binding state.  Hydrogen-bonding of cb5 to both domains of 
cb5r is reasonable in the view of the modulation of cb5r/cb5 complex formation by the 
NADH binding (Meyer et al., 1995). 
In order to prove that the ionic interactions and specific chemical bonding 
between these two proteins are exact, cb5r and cb5 mutants were constructed by means of 
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bacterial expression and site-directed mutagenesis (Strittmatter et al., 1992).  In this 
study, the amino acids that are believed to interact are lysine residues K41, K125, K162, 
and K164 in cb5r and glutamate residues E47, E48, E52, E60 and aspartate residue D64 
in cb5.  The activity of cb5r mutants was measured with potassium ferricyanide as an 
electron acceptor; it was found that the activity in the mutant was almost the same as that 
of the cb5r wild type.  This suggests that electron transfer from NADH to cb5r remains 
intact in all mutants.  Also the specific activity of all cb5r mutants was reported to be 
considerably less efficient than that of the wild type, and the Km values were significantly 
elevated when the wild type cb5 was used as the electron acceptor (Table 9).  
 
 
Table 9: Kinetic Properties of Cb5r Mutants Using Human Erythrocyte Wild-Type 
Cb5. (Shirabe et al., 1998) 
 
  This result may be explained by the fact that the residues from cb5 that are 
involved in the interaction with cb5r are negatively charged and normally are neutralized 
by the positive charge of the cb5r residues.  The difference in this case is that the cb5r 
mutants have lost their positive charge.  From these results it can be concluded that the 
four lysine residues K41, K125, K162, and K163 may participate in the electrostatic 
interaction with cb5 (Shirabe et al., 1998).  Based on the same study, cross-linking studies 
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of the binding of residues E47, E48, E52, E60, and D64 (group A residues) of cb5 with 
cb5r were undertaken.  Cb5 mutants of the glutamate residues were generated.  One or all 
of these residues were changed to Ala.  The obtained Km and Kcat values were not 
significantly different than those of the wild type, indicating that none of these residues 
participates in the interaction with cb5r. The role in binding to cb5r by other acidic 
residues located close to the heme group of cb5 was examined.  The substitution of E41, 
E42, D57, and E63 (group B) with Ala caused a five-fold increase in the Km with no 
notable change in the Kcat.  This indicates that some of the group B residues participate in 
the interaction of cb5 with cb5r (Shirabe et al., 1998). 
 
Role in Drug Metabolism and Involvement in the Detoxification of Xenobiotics 
through Cytochrome P450 
 
 
In the past few decades, hundreds of experiments have been performed to study 
the effect and the mechanism of action of the NADH, NADPH, cb5r, cb5, P450 reductase, 
and P450 sequence of reactions on the substrate metabolism of P450 (Vergeres & 
Waskell, 1995).  Cytochrome P450 is a mixed function oxidase which catalyzes the 
oxidation of numerous endogenous and exogenous compounds (Siegel et al., 2007).  The 
activation of P450 for oxidation of its substrates and activation of molecular oxygen, 
requires two electrons which are provided by NADPH or, possibly, cb5 (Ortiz de 
Montellano, 1986).  The first electron is transferred to P450 by NADPH P450 reductase 
while the second electron can either be transferred by NADPH P450 reductase or, as 
speculated, cb5 (Vergeres & Waskell, 1995).  Cb5 cannot transfer the first electron to 
P450 because the potential of cb5 is ~ 20 mV, while that of ferric P450 (that needs to be 
reduced to ferrous P450) is ~ -330 mV.  Therefore the reduction of P450 by 
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NADH/cb5r/cb5 chain of electron flow would be too slow to support the necessities of 
P450-dependent metabolism of various substances, including drugs (Fig. 12) (Porter, 
2002).  
 
Figure 12: Electron Transport Pathways to Cytochrome P450 in the Endoplasmic 
Reticulum. (Porter, 2002) 
 
After being reduced by NADPH and/or cb5, P450 reacts with oxygen to form an active 
oxygen complex, which in turn hydroxylates the various substrates (Gillette, 1971).  The 
reaction is as follows:  
- NADPH + A(P450)         AH2 + NADP 
 
- AH2 + O2         Active oxygen complex 
 
- Active oxygen complex + drug         Hydroxylated drug + A + H2O 
 
 As mentioned, when the source of reducing equivalents is NADH, the reduction 
of P450 is very slow, about 10% of the rate with NADPH, even in the case of the input of 
the second electron (Shenkman & Jansson, 1999).  Early studies on P450 indicated that 
the rate-limiting step in the monooxygenase reaction was the input of a second electron.   
It was also suggested that the role of cb5 was to speed up this electron transfer by 
providing the second electron more rapidly from NADH than could be provided from 
NADPH (Hildebrandt, 1971).  
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A hypothesis has been presented to explain this stimulatory effect of cb5. Cb5 
forms a two-electron acceptor heterodimeric complex with P450 that causes cb5 to 
stimulate the substrate oxidation by P450.  This would also allow for a single interaction, 
rather than two, with the reductase to provide the two electrons needed for the activation 
of molecular oxygen.  Cb5 was suggested to act by oxidizing ferrous P450, thereby 
allowing the input of a second electron to the oxidized P450, and then returning the 
electron to the oxyferrous P450 intermediate.  This function of cb5 was suggested to be 
due to the need for only single interaction with NADPH-P450 reductase by the 
heterodimeric complex rather than two separate interactions with P450 alone (Shenkman 
& Jansson, 1999). 
 
Phylogenetic Analysis of P. falciparum Cb5r and Cb5 
 
 
  Cb5r and cb5 have a high pharmacological significance due to their role in drug 
metabolism and detoxification of xenobiotics.  With the increasing levels of drug 
resistance to essentially all of our available antimalarial medicines, there is an urgent 
need to find new parasitic drug targets.  A new important aspect that has not yet been 
mentioned in this review, is the identification of plant cb5r as a novel herbicidal target 
(Reindl, 2005), thus making this class of agents as potential candidates for new anti-
parasitic drugs against P. falciparum malaria. The phylogenetic relationship between 
plant and P. falciparum cb5r and cb5 is a useful tool to evaluate the evolutionary distance.    
Analyzing the phylogenetic tree can give us precious insights into the possible 
relatedness of these proteins which belong to these two different kingdoms (plantae and 
protista, respectively).  
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Plasmodium falciparum cb5r formed a distinct clade with other protozoan, having 
the closest homology to plants, and all protozoan isoforms were distinct from their 
mammalian orthologues (Fig. 13).  Considering that plant cb5r is an herbicidal target, it 
can be speculated that P.falciparum cb5r may also represent a potential novel drug target.  
An additional consideration that can be extrapolated from the phylogenetic tree is that 
protozoan cb5r is more closely related to plant cb5r than mammalian cb5r.  This is a 
further advantage in terms of novel drug target and drug efficacy: the closeness in the 
evolutionary course of protozoan cb5r to plant cb5r may lead to promising treatment 
outcomes.  This is further supported by the fact that the host cb5r (human) will not be 
affected by the action of the drug since human cb5r is phylogenetically too far away from 
its protozoan orthologue.  
 
 
 
Figure 13: Phylogram of Cytochrome b5 Reductases. 
Amino acid sequences of cb5r were aligned using ClustalW. 
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   P. falciparum cb5 also formed a distinct clade separate from their mammalian 
orthologues (Fig. 13a).  The oldest cb5 orthologues are found in prokaryotes, including 
purple bacteria and Gram-positive species. 
 
 
 
Figure 13a: Phylogram of Cytochrome b5. 
Various cb5 amino acid sequences were aligned using ClustalW. 
 
 
Structural Comparison of P. falciparum Cb5r with Mammalian Cb5r and Other Species 
 
 
 Several cb5rs from a variety of species were aligned using ClustalW and Jalview 
to compare the sequences of the four conserved binding motifs (Fig.14a, 14b, 14c).  In 
particular, Plasmodium falciparum and mammalian cb5r were analyzed.  In the flavin-
binding domain, at the second amino acid position, P. falciparum has a serine (S) while 
human cb5r has a proline (P); also, in the same domain, at the sixth position, there is a 
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valine (V) in P. falciparum cb5r and an isoleucine (I) in the human code.  Lastly a 
tyrosine (Y) in P. falciparum and a serine (S) in human are found at the seventh position.    
There are a total of three substitutions in amino acids in the flavin-binding domain 
sequence (which consists of seven amino acids) between P. falciparum and human cb5r.   
P. falciparum cb5r only shares two differences with the other mammalian species 
presented here: Pro becomes Ser and Ser becomes Tyr in mammalian and P. falciparum, 
respectively.  Compared to many plant and parasite species, P. falciparum cb5r shares 
many differences, especially in the first two and last two amino acids. P. falciparum cb5r 
is the also the only protein with a Tyrosine at the seventh position in the flavin-binding 
domain.  The third, fourth, and fifth amino acid in the domain are conserved throughout 
the species (Fig. 14a). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 14a: Amino Acid Sequence Alignment with the First Two Binding Motifs by 
ClustalW Analysis and Jalview. 
Comparison of mammalian with P. falciparum cb5r shows three amino acid substitutions in the FAD-
binding motif: Pro       Ser, Ile      Val, and Ser       Tyr. The 9-amino acid gap preceding the FAD/FMN 
selectivity motif that is present in many fungal and plant cb5rs, is reduced to a 2-amino acid gap in P. 
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falciparum. This gap is absent in mammalian cb5r.  This gap may decrease the stability of the protein and 
could serve as a new target for the development of anti-parasitic drugs. 
 
 
The first NADH-binding domain has the signature sequence GxGxxP.  The 
sequences in mammalians are very conserved, all being GTGITP, while P. falciparum 
has GTGMTP, with only one substitution from Isoleucine (I) in mammalians to 
Methionine (M) in the parasite.  The presence of Met at the fourth position is unique to 
P.falciparum (Fig. 14b). 
 
 
 
Figure 14b: Continued Amino Acid Sequence Alignment Containing the First 
NADH-binding Motif by ClustalW Analysis and Jalview. 
The NADH-binding motif is very conserved and has the signature sequence GxGxxP. In all mammalians 
the sequence is GTGITP, while the P. falciparum one is GTGMTP. Here the only substitution is Ile that 
becomes Met in P. falciparum. The presence of Met at the fourth position is unique to P.falciparum. There 
is a 16-amino acid gap preceding the NADH-binding motif in fungi and plants that is reduced to a 5-amino 
acid gap in P. falciparum. This gap is also seen as a potential novel drug target. 
 
    
 There is a 9-amino acid gap preceding the FAD/FMN selectivity motif in many 
fungal and plant species which corresponds to a “lid” that covers the FAD prosthetic 
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group in all mammalian and Trypanosoma species (T. brucei and T. cruzi), and in 
Leishmania infantum as well.  This variation in the protein structure may decrease the 
stability of the molecule and could be consider as a target in the design of drugs.  This 
gap in P. falciparum cb5r is made up of only two amino acids so its properties should be 
investigated (Fig. 14a & 15). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 14c: Continued Amino Acid Sequence Alignment with the Second NADH-
binding Motif by ClustalW Analysis and Jalview. 
This second NADH-binding domain is extremely conserved throughout the organisms. Mammalian and P. 
falciparum cb5r possess exactly the same sequence in the NADH-binding domain. All possible sequences 
are also presented in bold below the Jalview alignment. 
 
 
 There is another larger 16-amino acid gap in the sequence preceding the NADH-
binding motif in all fungal and plant species.  This gap is absent in all mammalian 
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species.  This region connects the NADH- and FAD-binding motifs and it is represented 
by two β-sheets which are missing in those species that lack this 16-amino acid sequence.   
This also decreases the stability and catalytic efficiency of the protein and may constitute 
a potential target in the development of novel drugs.  There is only a 5-amino acid 
sequence gap in the structure of P. falciparum cb5r (Fig. 14b & 15).  
 
 
Figure 15: The Ribbon Model of Rat and Candida Cb5r. 
This model compares a mammalian (rat) cb5r to a fungal (Candida) cb5r. In the absence of a ribbon model 
of P. falciparum cb5r, it shows the lack of the “lid” (9-amino-acid gap) over the FAD prosthetic group in 
Candida (only partial in P. falciparum) and the lack of two β-sheets (16-amino acid gap) in the region that 
connects the NADH- and FAD-binding motifs in Candida (only partial in P. falciparum). 
    
 
The amino acid sequences of the species that were aligned and analyzed by 
ClustalW and Jalview were also evaluated by separating them into their catalytic 
domains.  From this separation, phylograms were created that reflected the evolution of 
the individual separated domains.  The first amino acid sequence contains the first two 
domains (NADH-binding domain and the FAD/FMN selectivity domain) and the second 
amino acid sequence includes the third and fourth domains i.e. the first and second 
NADH-binding domain.  
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Cytochrome b5 Reductases Amino Acid Sequence Containing the FAD-binding Domain 
and the FAD/FMN Selectivity Domain (Underlined are the Two Domains) 
 
>Human -CytB5Red AAP88823.1 [Homo sapiens] 
MGAQLSTLGHMVLFPVWFLYSLLMKLFQRSTPAITLESPDIKYPLRLIDREIISHD
TRRFRFALPSPQHILGLPVGQHIYLSARIDGNLVVRPYTPISSDDDKGFVDLVIKV
YFKDTHPKFPAGGKMSQYLESMQIGDTIEFRGPSGLLVYQGKGKFAIRPDKKSNP
IIR 
>Chimp -CytB5Red XP_001171082.1 [Pan troglodytes] 
MGAQLSTLGHVVLFPVWFLYSLLMKLFQRSTPAITLESPDIKYPLRLIDREIISHDT
RRFRFALPSPQHILGLPVGQHIYLSARIDGNLVVRPYTPVSSDDDKGFVDLVIKVY
FKDTHPKFPAGGKMSQYLESMQIGDTIEFRGPNGLLVYQGKGKFAIRPDKKSNP
VIR 
>Rat -CytB5Red P20070 [Rattus norvegicus] 
MGAQLSTLSRVVLSPVWFVYSLFMKLFQRSSPAITLENPDIKYPLRLIDKEIISHDT
RRFRFALPSPQHILGLPIGQHIYLSTRIDGNLVIRPYTPVSSDDDKGFVDLVVKVYF
KDTHPKFPAGGKMSQYLENMNIGDTIEFRGPNGLLVYQGKGKFAIRADKKSNPV
VR 
>Dog -CytB5Red ABA12483.1 [Canis familiaris] 
MGAQLSTLGHVVLSPVWFLYNLLMKLFQRSTPAITLESPDIKYPLRLIDKEVINHD
TRRFRFALPSPQHILGLPVGQHIYLSARIDGNLVIRPYTPVSSDDDKGFVDLVIKV
YFKDTHPKFPAGGKMSQYLESMKIGDTIEFRGPNGLLVYQGKGKFAIRPDKKSN
PIIK 
 
>Chicken -CytB5Red XP_416445.1 [Gallus gallus] 
MGAQLSTLGWVVTYPLWLIYSTIRRLFGSPRPAITLKDPEVKYALRLIDKEEVSH
DTRRFRFALPSVDHVLGLPIGQHIYLSARIDGALVVRPYTPISSDDDKGFVDLVIK
VYMKGVHPKFPDGGKMSQYLDNLKIGDTIDFRGPSGLLVYKGKGEFAIRPEKKA
DPVTK 
>Xenopus -CytB5Red AAH45265.1 [Xenopus laevis] 
MGAQLSTVSRILTSPFWFIFSIFQRFFGKPRPAITLESPDIKYALRLIDREEISHDTRR
FRFALPSPEHVLGLPIGQHIYLSARVDGNLVVRPYTPVSSDDNKGYVDLVVKIYF
KNVHPKFPEGGKMSQYLDSLRKDETIDFRGPSGLLVYSGKGTFQIRPDKKSPPVP
K 
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>Zebrafish -CytB5Red AAQ97765.1 [Danio rerio] 
MSYAMSTTVAVTVGVVLVSTAGLLGYYYFNRKRKILITLIDPSEKYKLRLVDKEI
ISHDTRRFRFALPSPEHVLGLPVGKHVYLSARIDGNLIVRPYTPVSSDDDKGFVDL
VVKIYFRDVHPKFPEGGKMSQYLESLRIGDVIDFRGPGGLLEYKGAGRLDIQADK
KAPAETK 
>Drosophila -CytB5Red AAF50004.1 [Drosophila melanogaster] 
MTEFDFVPLAVGVVAVLAGALIVHYLLNKKSTKPRREPNRTARLRTLVDPNDKY
LLPLIEKENLSHDTRRFRFGLPSKQHVLGLPVGQHIHLIATIDNELIIRPYTPISSDE
DVGYVDLVVKVYFKDSHPKFPAGGKMTQHLEQLELGDKISFRGPSGRLQYLGN
GTFSIKKLRKDPPKHV 
>Caenorhabditis_elegans -CytB5Red AAB66010.1 [Caenorhabditis elegans] 
MVENNTLAITGGVVLISSVSLFLYLRQLRAEKKSKRTLEDDSVKYLLPLIEKFEIS
HNTRKFRFGLPSKDHILGLPIGHHVYLSANIGGKLIVRSYTPVSCDLDLGYVDLM
VKVYFKNTHERFPDGGKMSQHLESLKIGDTVSFRGPHGSIIYKGSGLFTVRMDK
KAEPKNR 
>Saccharomyces_cerevisiae_CBR1_[ER] (Z28365) 322aa  ScCBR1 
MYKYSYYIRRKNEREKKVLKVCIQLALQQETQSIKQSKMAIDAQKLVVVIVIVV
VPLLFKFIIGPKTKPVLDPKRNDFQSFPLVEKTILTHNTSMYKFGLPHADDVLGLPI
GQHIVIKANINGKDITRSYTPTSLDGDTKGNFELLVKSYPTGNVSKMIGELKIGDSI
QIKGPRGNYHYERN 
 
>Saccharomyces_cerevisiae_MCR1_[Mito]  -(Z26877)  302aa  ScMCR1 
MFSRLSRSHSKALPIALGTVAIAAATAFYFANRNQHSFVFNESNKVFKGDDKWID
LPISKIEEESHDTRRFTFKLPTEDSEMGLVLASALFAKFVTPKGSNVVRPYTPVSD
LSQKGHFQLVVKHYEGGKMTSHLFGLKPNDTVSFKGPIMKWKWQPN 
>Candida_albicans_CBR1_[ER] –CaCBR1 chr4 (294aa) EAK92238 [Candida albicans 
SC5314] 
MSETTTVPPIETVSEPNPFIVFATVATIISAFIGYYFLQQSKKHTPVLKPDEFQKFPL
IEKIRVSHNSAIYRFGLPKSTDRLGLPIGQHISIGATIDGKEVVRSYTPISTDDQLGH
FDLLIKTYENGNISRHVAGKNVGEHIEIRGPKGFFTYTPN 
 
>Candida_albicans_MCR1_[Mito]  –CaMCR1 chr6(301aa) XM_705739 [Candida 
albicans SC5314] 
MLTHHLSKLATPKFLVPFAGATALSIGLALQYSTSNNYIANETGKTFTDSNEWVD
LKLSKSIDLTHNTKHLVFKLKDENDVSGLITASCLLTKFVTPKGNNVIRPYTPVSD
VNQSGEIDFVIKKYDGGKMSSHIFDLKEGETLSFKGPIVKWKWEPN 
 
>Candida_glabrata –CytB5Red XM_448811 [Candida glabrata CBS138] 
MDGIKILATFSVLVLFYKLFTYSKKGGVSQKEAVKALLKTEFREFELVEKEQLTH
NTAKYKFKLADESHVLGLPIGQHITVKTIIGGKPVSRSYTPTSLDEECVGFFELLV
KSYPEGNISKHIGDMKIGEKINISGPRGFYEYVPN 
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>Cryptococcus_neoformans_CBR1_[ER] –CnCBR1(AAW46852, 294 aa, C. neoformans 
JEC 21 strain, chr 13) 
MFTIEVLAQKLAPHASFLGGLVVAAILGLFIFFQEKDRKVLDPVEWRSFKLVDKD
HLSHNTALYRFALPRASDSLGLPIGQHISVAAEINGKQVVRSYTPTTLDDDKGHF
DLVVKTYEKGNISRYLSLLTIGQEIKVKGPKGKFVYTPN 
 
>Cryptococcus_neoformans_MCR1_[Mito]  –CnMRC1(XM_572314 , 352 aa, C. 
neoformans JEC 21 strain, chr 8) 
MAAARFLSSARIARPSVISRTAAQYRGYSSAAPSGGANWPLLLSVAGATGVGAY
AYLQYNPSVKKEVEAKIKGAEAEKAAAERTAAGISAFVKDTWIPFTLEKVGKYN
HNTNIYHFSFGEEGKDKISGGEVASVVLLRSPEGPEQIKDEKDKPIIRPYTPISPPD
QKGSIEFMIKSYSGGKFTPFLSNLSPGQQVLFKGPLQKFKYQPN 
 
>Mortierella -CytB5Red (AB020034) [Mortierella alpine] 
MTLSNPAIAAASGVILAGAYLIDPSALPFVAAGVAATWARVLFKKTAVKTPPMD
PKEYRKFKLVDKVHCSPNTAMYKFALPHEDDLLNLPIGQHISIMANINGKDISRS
YTPTSSSDDVGHFVLCIKSYPQGNISKMFSELSIGDSINARGPKGQFSYTPN 
 
>Physarum_[slime_mold] -CytB5Red (AB259870) [Physarum polycephalum] 
MTVTQLLTSLSFEAKLGIVIAAAAVVVISKFAFGSSSSKREPALNPNEYKKFMLRE
KQIINHNTRLFRFNLHHPEDVVGLPIGQHMSVKATVDGKEIYRPYTPVSSDDEKG
YFDLIIKVYEKGQMSQYIDHLNPGDFLQVRGPKGQFDYKPN 
 
>Leishmania_infantum -CytB5Red (L.infantum clone JPCM5, MCAN/ES/98/LLM-
877; 308 aa) 
MVGVLVIIAFSMAAFFAFMFTRTTKVAMDPTMFKHFKLIKRTEVTHDTFIFRFAL
ENETQTLGLPIGQHIVLRADCTTAGKTETVTHSYTPISSDDEKGYVDFMIKVYFA
GVHPSFPHGGRLSQYMYHMKLGEKIEMRGPQGKFIYLGNGTSRIHKPGKGIVTE 
 
>Leishmania_braziliensis -CytB5Red (XM_001563404) [MHOM/BR/75/M2904; 275aa] 
MQQSEHLAASCAKAPVNTFTSDEYKPFKLISSRYESHDTRRFYFALDSADDSFYM
PVASCIIAKYTDADGKDVARPYTPISSNSTKGHFELLVKKYPKGKMGNHLFAMQ
PGDELLIKGPFEKFAYKPN 
 
>Leishmania_major -CytB5Red (XM_001685505) [strain Friedlin; 338aa] 
MAKFMTFGAATALGAAFHTYTSSQRMAAECAAKKEAFTTKFKPFVLGEVLNLA
EDVAIFRFLLNDPSDVFDLVPCSTLQAHFKEGANMVDQPMRFYTPITPNGTKGYF
DLLVKKQRPGRFTEHLFSMDVGESLLFRAIQYKLTYKKN 
 
>Trypanosoma_brucei -CytB5Red (XP828456; 307 aa, TREU 927/4 GUTat 10.1 clone) 
MMLAVIVAFAVIFFVTLALAGRGLLPFYRYPPIALNPDVYQSFKLVKKTRVTHDS
FIFRFALHASHQCLGLPTGHHIRFRVASKHNFTGTPQVVQHSYTPISSNDDKGFVD
FLVKIYYKGSNPAFPNGGRLSQHLDSLSIGEAVEMLGPVGKFQYMGNGDYTVE
MGKGEVKRQ 
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>Trypanosoma_cruzi -CytB5Red (XP807822; 306 aa, CL Brener strain) 
MLTYVVAAVIIVLTVFLFFKKGVFFSSSMGVALDASKFQNFKLVDKITVSHNSFIF
RFALHSPTQRLGLPIGQHLHIRCMTTNPDGKPEMVQHAYTPVSSDDDLGHVDFLI
KVYFKNVHPNFPNGGRLSQHLYDLPLGTMVEIRGPVGNFEYLGKGNYTVKDGK
GKLKKM 
 
>Plasmodium_falciparum –CytB5Red (XP_001350386; 362 aa, strain 3D7) 
MKRSFRSMLRSIFMRILYFLTSNISSIIIFCVSISFLGYFGKELHNNNKLFNLYSKKH
EYEELDTKEKSQEKPFLNGKNQSFKLYKIIKLTPTVKIFIFSYPDEYEYLGLGICKH
IKFNASNIEGKIKGKWNNNDDKEKNLKQISRSYTPVYIDKKKKHVHFIIRVYYPD
DEYIDGGKMSIQLNKLNNNDEIDINGPFGLLEYKGNNELLHLSKSVK 
 
>Arabidopsis -CytB5Red (Arabidopsis thaliana, NM_121783) 
MDTEFLRTLDRQILLGVFVAFVAVGAGAAYFLTSSKKRRVCLDPENFKEFKLVK
RHQLSHNVAKFVFELPTSTSVLGLPIGQHISCRGKDGQGEDVIKPYTPTTLDSDVG
RFELVIKMYPQGRMSHHFREMRVGDHLAVKGPKGRFKYQPG 
 
>Squash -CytB5Red (Cucurbita maxima, AF274589) 
MAAFLRRLATAAPALRYNALCGQSRIESSKFRFPIGTITAVTAGFSYMFYASTSNL
VHLAPNCEEDGQKVALKPDKWIEFELQDVARVSHNTNLYRFSFDPSENWGWML
LHASLQELQLIKTNRGEVKYVARSYTPISDPEAKGYFDLLIKIYPQGKMTQHFAK
LKPGDKLEVKGPIRKLKYSPN 
 
>Maize -CytB5Red (Zea mays, AF077372) 
MDFLQEQRFYSVETTVAVAVAVAAVAAGGAFLLLRSRKPKGCLDPENFRKFKL
VEKKQISHNVARFKFALPTPTSVLGLPIGQHISCRGQDATGEEVIKPYTPTTLDSD
LGYFELVIKMYPQGRMSHHFREMKVGDYLSVKGPKGRFKYH 
 
>Rice -CytB5Red (Oryza sativa (japonica cultivar-group), NM_001051147) 
MDLLHGESVQTTVAIAVAVVAVAAGGAFLLLRSRKPKGCLDPENFKKFKLVEK
KQISHNVARFKFALPTPTSVLGLPIGQHISCRGQDATGEEVIKPYTPTTLDSDLGH
FELVIKMYPQGRMSHHFREMKVGDYMSVKGPKGRFRYQ 
 
>Chlamydomonas_[green_alga] -CytB5Red (Chlamydomonas reinhardtii(green algae), 
XM_001695672) 
MRSVITLLSYWQVGAGLLVVLVLIQALVFLRKKTKKPFLDPSEFQPVPLVEKTLIT
HNTVRLRFALPDPEQRVGLPIGQHISFKAQGEDGKDVIRPYTPVSDDDQLGAVDF
VIKLYPTGKMSQVIAKMQLGDTMLMKGPKGRFTYT 
 
>Tung-oil_Tree -CytB5Red (Vernicia fordii, AY819697) 
MDLEFLQTLDVQILVGVAVAVLAIGIGAVFLFSSKKPKGCLDPENFKDFKLVNRT
QLSHNVAKFSFALPTPTSVLGLPIGQHISCRGKDSQGEEVIKPYTPTTLDSDVGHF
ELVIKMYPQGRMSHHFREMRVGDYLSVKGPKGRFRYQ 
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The phylogram below (Fig. 16) depicts the evolutionary distance among all the 
different species based on the first catalytic domain containing the FAD-binding domain 
and FAD/FMN selectivity domain.  P. falciparum and other parasites belong to a clade 
different from the mammalian species and have the closest homology to fungal species.   
Also plants form a distinct clade which is very far from the mammalian one, reflecting a 
high evolutionary distance and a high degree of amino acid substitution between the two 
groups. 
 
 
Figure 16: Cb5r Phylogram According to the First Half of the Protein Containing 
the FAD-binding Domain and the FAD/FMN Selectivity Domain. 
P.falciparum along with other parasites and mammalian belong to two distinct clades. The closest 
proximity for P. falciparum is to fungal species. A high evolutionary distance between plants and 
mammalians is also observed in this phylogram. 
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Cytochrome b5 Reductases Amino Acid Sequence Containing the First and Second 
NADH-binding domain (Underlined are the Two Domains) 
 
>Human -CytB5Red AAP88823.1 [Homo sapiens] 
TVKSVGMIAGGTGITPMLQVIRAIMKDPDDHTVCHLLFANQTEKDILLRPELEEL
RNKHSARFKLWYTLDRAPEAWDYGQGFVNEEMIRDHLPPPEEEPLVLMCGPPP
MIQYACLPNLDHVGHPTERCFVF* 
 
>Chimp -CytB5Red XP_001171082.1 [Pan troglodytes] 
TVKSVGMIAGGTGITPMLQVIRAIMKDPDDHTVCHLLFANQTEKDILLRPELEEL
RNEHSARFKLWYTLDRAPEAWDYSQGFVNEEMIRDHLPPPEEEPLVLMCGPPPM
IQYACLPNLDRVGHPKERCFAF* 
 
>Rat -CytB5Red P20070 [Rattus norvegicus] 
TVKSVGMIAGGTGITPMLQVIRAVLKDPNDHTVCYLLFANQSEKDILLRPELEEL
RNEHSSRFKLWYTVDKAPDAWDYSQGFVNEEMIRDHLPPPGEETLILMCGPPPM
IQFACLPNLERVGHPKERCFTF* 
 
>Dog -CytB5Red ABA12483.1 [Canis familiaris] 
TVKSVGMIAGGTGITPMLQVIRAIIKDPHDPTVCHLLFANQTEKDILLRPELEELR
NEHSARFKLWYTVDKAPEAWDYSQGFVNEEMIRDHLPPPEEEPLILMCGPPPMI
QYACLPNLDRVGHPKERCFAF* 
 
>Chicken -CytB5Red XP_416445.1 [Gallus gallus] 
KVKYVGMIAGGTGITPMLQIIRAIMKDKDDGTVCQLLFANQTEKDILQRSELEEI
QVQHPNRFKCWYTLDKAPENWDYSQGFVNQDMIRDHLPPPQSDVLILMCGPPP
MIQYACIPNLDKLGYAKDMRFAF* 
 
>Xenopus -CytB5Red AAH45265.1 [Xenopus laevis] 
KANHLGMIAGGTGITPMLQLIRAILKDKEDKTICYLLFANQTEKDILLRSELEEIR
ANHPSRFKLWYTLDRAPEDWDYSQGFVNEDMISSFMPPPGDDVLILMCGPPPMV
QYAINPSLDKLSYPQDRRFAY* 
 
>Zebrafish -CytB5Red AAQ97765.1 [Danio rerio] 
TVKSLGLIAGGTGITPMLQLIRDITKNPNDTTTCSLLFANQTEKDILLKDELEEIQA
RHSDRFKLWFTVDRAPADWEYSQGFISAEMIQDHLPPPSDDSMILMCGPPPMIQF
ACNPNLDKLGYRQSQRFAY* 
 
>Drosophila -CytB5Red AAF50004.1 [Drosophila melanogaster] 
TAKRVNMIAGGTGITPMLQLAREVLKRSDKDKTELALLFANQSEKDILLRAELDE
LAQKHPDQFKIWYTVDKANEGWQYSVGFINEEMIAAHLLPAKDDTIVLLCGPPP
MINFACNPALDKLGYHPDTRFAY* 
 
>Caenorhabditis_elegans -CytB5Red AAB66010.1 [Caenorhabditis elegans] 
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FFKHLSMIAGGTGITPMLQVIAAILRDPIDATQIRLLFANQTEDDILCRKELDELAE
KHPTRFRVWYTVSKASKDWRYSTGHINEEMIKEHLFPSNEESAVLLCGPPAMIN
CACIPNLDKLGHNSENYLIF* 
 
>Saccharomyces_cerevisiae_CBR1_[ER] (Z28365) 322aa  ScCBR1 
CRSHLGMIAGGTGIAPMYQIMKAIAMDPHDTTKVSLVFGNVHEEDILLKKELEA
LVAMKPSQFKIVYYLDSPDREDWTGGVGYITKDVIKEHLPAATMDNVQILICGPP
AMVASVRRSTVDLGFRRSKPLSKMEDQVFVF* 
 
>Saccharomyces_cerevisiae_MCR1_[Mito]  -(Z26877)  302aa  ScMCR1 
QFKSITLLGAGTGINPLYQLAHHIVENPNDKTKVNLLYGNKTPQDILLRKELDAL
KEKYPDKFNVTYFVDDKQDDQDFDGEISFISKDFIQEHVPGPKESTHLFVCGPPPF
MNAYSGEKKSPKDQGELIGILNNLGYSKDQVFKF* 
 
>Candida_albicans_CBR1_[ER] –CaCBR1 chr4 (294aa) EAK92238 [Candida albicans 
SC5314] 
MVKSFGMIAGGTGIAPMYQIITAILKNPEDKTKIHLVYANVTESDILLKEELDNFA
ARHPDRLKIHYVLNEAPANWQGSVGFVTPEIIDTHLPKASNDTNLLLCGPPPMVS
AMKKAAVELGFQKAKPVSKLGDQVFVF* 
 
>Candida_albicans_MCR1_[Mito]  –CaMCR1 chr6(301aa) XM_705739 [Candida 
albicans SC5314] 
QFKSIALIGGGTGITPLYQLLHQITSNPKDNTKVNLIYGNLTPEDILLKKEIDAIASK
HKDQVKVHYFVDKADEKKWEGQIGFITKEFLQKELEKPGSDFKVFVCGPPGLYK
AISGPKVSPTDQGELTGALKDLGFEKEHVFKF* 
 
>Candida_glabrata –CytB5Red XM_448811 [Candida glabrata CBS138] 
VHKHLAMVAGGTGITPMFQIMKAIARDPSDKTRVTLLYGNVLEEDILLKQELDD
LVKQRPDQFKITYLLDKPERDDWEGGVGYVTLDLMKESFPSAEEDVQLLVCGPP
GMVSSVKRNAVALGFPRAKPVSKMEDRVFVF* 
 
>Cryptococcus_neoformans_CBR1_[ER] –CnCBR1(AAW46852, 294 aa, C. neoformans 
JEC 21 strain, chr 13) 
MAPHLVMIAGGTGITPMYQIIKSSIKTPGDKTRLSLIYANIQEDDILLKKEIDELQA
KSNGRFDVKYVLNNPPEGWTGGVGFVTKEMIEEAMPSSGVGSANHGEGHKVL
MCGPPPMITAMKGHLAQIGYPAPRSVSKLEDQVFLF*  
 
>Cryptococcus_neoformans_MCR1_[Mito]  –CnMRC1(XM_572314 , 352 aa, C. 
neoformans JEC 21 strain, chr 8) 
SFEKGLCIAGGSGITPMWQLINHSLSIPEDKTKWTLIYSNVSEADILLRKEFDALA
QKYPGRLDIKYVLDKGPWGWKGETGYVTADLIKKTFPKNEGENIRAFVCGPPGQ
MKAVSGEKDGMKQGELAGALKELGYTSDEVFKY* 
 
>Mortierella -CytB5Red (AB020034) [Mortierella alpine] 
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MCRAIGMIAGGTGLTPMLQIIRAIVKNPEDKTQVNFIFANVTEEDIILKAELDLLSQ
KHPQFKVYYVLNNAPEGWTGGVGFVNADMIKEHMPAPAADIKVLLCGPPPMVS
AMSKITQDLGYDKVNAVSKLPDQVFKF* 
 
>Physarum_[slime_mold] -CytB5Red (AB259870) [Physarum polycephalum] 
MVKEMGMIAGGTGITPMLQVARAIIKNPKEKTIINLIFANVNEDDILLRTELDDM
AKKYSNFKVYYVLNNPPAGWTGGVGFVSADMIKQHFSPPSSDIKVMMCGPPMM
NKAMQGHLETLGYTPEQWFIF* 
 
>Leishmania_infantum -CytB5Red (L.infantum clone JPCM5, MCAN/ES/98/LLM-
877; 308 aa) 
KVDAYAAIAGGTGITPILQIIHAIKKNKEDPTKVFLVYGNQTERDILLRKELDEAA
ANDSRFHVWYTIDREATPEWKYDIGYVCEEMFRKHLPVPDMLGSDSVPQNAGI
KKVMALMCGPPPMVQMAIKPNLERIGYTADN 
 
>Leishmania_braziliensis -CytB5Red (XM_001563404) [MHOM/BR/75/M2904; 275aa] 
MWKHVGMIAGGTGIAPMYQVIRAVLENPKDKTNISLIYASNQRRDILLANELIEM
QKIYNNFNMYLTLLEVPHRWLGGIGYVNSAMVTTFMPKPGEKNTKILVCGPPPM
MQAISGDKLFEPGKPPQQGPVGGLLETLGYKEDQVFKY* 
 
>Leishmania_major -CytB5Red (XM_001685505) [strain Friedlin; 338aa] 
RWTDVGMICGGTGLCPILQFMNASLETEGDSTRLNMLFANRSEKKILLKGLLDE
KAREHKDRLQIFYTVDNFDDPDIIANPVYKKGAPLTVDVASQPSTSPDGRKYFHG
FKGYIDVPMLQATMPRPSPSTLLLVCGPDPMMVKVVGAAPMVLRAMSGGLAY
QPSGAVLNNAADVSGFLGTLGYQKEMVYRF* 
 
>Trypanosoma_brucei -CytB5Red (XP828456; 307 aa, TREU 927/4 GUTat 10.1 clone) 
HVAGFAMVAGGTGITPMMQIIHAILKSPEDPTRLWLVYSNHTEEDILLRDALAEA
CKDPRVKVWHTLTRSAPPDWAYGRGRVNEEMLRTHLPPPQLEEGSVTVLLCGP
PLMLQDAVKPNLLNIGYSQDNIFTF* 
 
>Trypanosoma_cruzi -CytB5Red (XP807822; 306 aa, CL Brener strain) 
HTDAFTMVAGGTGITPMMQLIRAIMKNKEDRTNIFLVYANQTEDDILLRKELDD
CAKDPRMKLWYMLDRETSPQWKYGTGYVDEATLRAHVPVLQPRNSDYNRVV
ALMCGPPPMLQKAVKPNLEKLGYTAEDMFSF* 
 
>Plasmodium_falciparum –CytB5Red (XP_001350386; 362 aa, strain 3D7) 
IKKHIVMIAGGTGMTPFFRLINHLLLTKEKELPSDPVYITFIYANRNENEILLKSIFD
DYENRFENFKRVYSVDKCLNTNQMGNFENIGFINEELLRKYVLKYEKLNIEVKN
KDTLILLCGPPPMTSSIKSILKDQIHMENIIVF* 
 
>Arabidopsis -CytB5Red (Arabidopsis thaliana, NM_121783) 
QFRAFGMLAGGSGITPMFQVARAILENPTDKTKVHLIYANVTYDDILLKEELEGL
TTNYPEQFKIFYVLNQPPEVWDGGVGFVSKEMIQTHCPAPASDIQILRCGPPPMN
KAMAANLEALGYSPEMQFQF* 
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>Squash -CytB5Red (Cucurbita maxima, AF274589) 
MKKHIGMIAGGTGITPMLQVIDAIAKNQDDITQVSLIFANVSADDILLKEKLDKL
AACHPNIKVFYTVSNPPRGWKGGKGHVSKDMIIKCLPSPGNDALILVCGPPGMM
KHICGPKNKDFTQGELGGLLKDLGYSKDMVFKF* 
 
>Maize -CytB5Red (Zea mays, AF077372) 
VGQVRAFGMLAGGSGITPMFQVARAILENPNDNTKVHLIYANVTYEDILLKDEL
DDMAKTYPGRFKIYYVLNQPPENWNGGVGFVSKEMIQSHCPAPAEDIQILRCGP
PPMNKAMAAHLDELNYTKEMQFQF* 
 
>Rice -CytB5Red (Oryza sativa (japonica cultivar-group), NM_001051147) 
VGQVRAFGMLAGGSGITPMFQVARAILENPNDITKVHLVYANVTHDDILLKEEL
DNMAKTYPDRFKIYYVLNQPPEVWNGGVGFVSQDMIKAHLPAPAEDIQILRCGP
PPMNKAMAAHLDELGYTKEMQFQF* 
 
>Chlamydomonas_[green_alga] -CytB5Red (Chlamydomonas reinhardtii(green algae), 
XM_001695672) 
PNMVKHFGMLAGGTGITPMFQVLNAILKNPRDTTSVTLLYGNLTEEDILLRKELD
ELVAMHGNRLTVYHVLNTPPVDKEWSGGSGFISSELIRTKFPAPSSDIMTLRCGPS
PMMVAMEKALTDLGYAEDKQFQF* 
 
>Tung-oil_Tree -CytB5Red (Vernicia fordii, AY819697) 
PGQVRAFGMLAGGSGITPMFQVARAILENPNDKTKVYLIYANVTYEDILLKQEL
DGLAANYPDRFKVYYVLNQPPEVWDGGVGFVSKEMIENHCPAPASDIQILRCGP
PPMNKAMAAHLEALDYTSDMQFQF* 
 
 The second half of the amino acid sequences of various cb5r containing the two 
NADH-binding domains presents interesting differences in terms of evolutionary 
distance compared to the cb5r first half (Fig.17).  P.falciparum has the greatest 
evolutionary distance from human.  Its closest homology is to other protozoan and fungal 
species.  Compared to the first half of the protein, this phylogram shows less 
ramifications and more highly grouped clades, suggesting that there has been a higher 
degree of conservation in the evolution of this two binding domain-containing part of the 
protein. 
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Figure 17: Cb5r Phylogram According to the Second Half of the Protein Containing 
the First and Second NADH-binding Domain. 
This phylogram assumes a very large evolutionary distance between this section of cb5r in P. falciparum 
and human. The closest homology for P. falciparum is to protozoan and fungal species. There is also a 
higher degree of evolutionary conservation in this segment of the protein. 
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OBJECTIVES 
 
 
 Cytochrome b5 reductase and its electron acceptor cytochrome b5 have been 
studied extensively over the last fifty years and a great variety of aspects has been 
investigated, leading to a plethora of information in the literature.  Their known roles in 
fatty acid desaturation and elongation, cholesterol biosynthesis, and cytochrome P450-
mediated detoxification of xenobiotic in many different organisms, ranging from 
mammalians to fungi and plants, have been explored by many scientists. 
In a time in which resistance to available medicines is emerging, and affecting the 
cure of numerous infectious agents, there is a need to discover new and promising 
therapeutic targets.  In particular malaria treatment is experiencing an unprecedented 
crisis in terms of efficacy, safety, and availability of antimalarial drugs.  Resistance to the 
most feared and aggressive form of malaria that is caused by Plasmodium falciparum, has 
developed to most of the available drugs, with the exception of Artemisinin.  The 
structure, function, biochemical and pharmacological properties (in particular the role in 
the detoxification of xenobiotics), and the interaction with other cytoplasmic proteins of 
P. falciparum, such as cytochrome b5 reductase and its electron acceptor cytochrome b5 
should be investigated. 
Cb5r and its electron acceptor cb5 may serve as potential drug targets but yet, 
there are no formal studies that have addressed this possibility.  An elucidation of the 
mechanisms and processes in which it is involved may generate important information 
about the possible role of these two proteins as drug targets.  Interestingly, phylogenetic 
analysis has revealed that P. falciparum cb5r is closely related to plant cb5r, and plant cb5r 
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has been identified as a novel herbicidal target.  If we are to base our decision on weather 
or not cb5r would be a fortunate target by comparing its position in the phylogenetic tree 
to that of plant cb5r, we would likely be prompt to give an affirmative answer.  
In this project, an analysis of the amino acid sequence, binding domains, and 
protein structure was undertaken.  Furthermore, cloning of P. falciparum cytochrome b5 
reductase and cytochrome b5, and the optimization of recombinant protein expression in 
E. coli was performed.  A further objective of this study is the biochemical and kinetic 
characterization of P. falciparum cytochrome b5 reductase in order to elucidate its 
enzymatic properties.  Here, a comparison with mammalian cb5r is necessary in order to 
identify differences in biochemical and kinetic activity.  A conclusive and useful aim of 
this study (that has not been investigated here) would be the pharmacological 
characterization of P. falciparum cb5r through the use of potential inhibitors of this 
enzyme.  There are a number of inhibitors that have been found to alter the enzymatic 
activity of human cb5r, but none of them has been tested as potential antiparasitic 
compounds against P. falciparum cb5r.  It is important to remember that, ideally, this 
drug should possess high specificity for the P. falciparum cb5r but minimal toxicity to the 
human host. 
Further research will be needed in order to obtain useful knowledge of the 
pharmacological properties of this ubiquitous enzyme and draw conclusions on its 
suitability as an opportune novel drug target. 
In this project, observing the biochemical and enzymatic behavior of cb5r and cb5 
can reveal very important information about the suitability of these two proteins as drug 
targets.  This investigation will open the doors for future studies that will have the 
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advantage of using these results and apply them to further studies involving the 
pharmacological characterization of cb5r and cb5 and drug trials. 
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MATERIALS AND METHODS 
 
 
The first step in this project to characterize a novel drug target must start with the 
source of all future assays: a purified protein.  The process that leads to the expression of 
a protein consists of cloning of the Plasmodium falciparum cb5r and cb5 genes, followed 
by optimization of the recombinant protein expression and further purification.  The 
membrane-bound form of the proteins will be used for this study; these are the truncated 
versions that lack the transmembrane domain since we are interested in characterizing the 
soluble form of the proteins. 
 
Experimental Design 
 
 For cloning of the desired genes coding for cb5r and cb5, a biotechnology 
company (GENEART, Würzburg, Germany) was employed to synthesize both genes 
obtained from the P. falciparum genome database.  Importantly, Plasmodium has an AT-
rich codon bias that complicates heterologous protein expression in E. coli.  Therefore, 
for synthesis of the genes, we designed the P. falciparum cb5r and cb5 using codon 
optimization for E. coli to obtain optimal protein expression.  Both synthesized genes 
were subcloned into the vector plasmid vector called pTWIN (New England Biolabs).  
This vector has several features: (a) the expression of the fusion gene is under the control 
of the T7 promoter and is regulated by IPTG due to the presence of a lacI gene and (b) 
that the expression requires an E. coli host that carries the T7 RNA polymerase gene 
[ER2566, BL21 (DE3) and derivatives].  Each primer also contains a His6-tag, an Intein 
protein, and a Chitin Binding Domain (CBD) fragments for further protein purification.  
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When the genes have been successfully inserted into the plasmid, the transformation into 
bacterial cells could proceed.  This was where the actual project begun.  The bacteria 
used for this purpose was E. coli BL21 (DE3) RIPL, which is a special strain of bacteria 
optimized for heterologous protein expression.  
Cells were grown in the presence of LB broth and plated on Terrific Broth (TB) 
agar containing 100µg/ml ampicillin.  Our original genes that were ligated into plasmids 
contained an ampicillin-resistant gene that allowed growth of those cells that retained the 
plasmid.  Positive clones were then sequenced to confirm that no mutations occurred 
during the cloning process.  Followed transformation, minipreparation of bacterial 
plasmid DNA and digestion of minipreparation by restriction enzyme were performed.   
Agarose gel electrophoresis was then performed to obtain a DNA gel in which the bands 
corresponding to the base pairs number of plasmid and insert could be observed. 
 Optimization of recombinant protein expression was determined according to 
temperature (23 ºC), time of induction (16 hours), and IPTG concentration (0.2, 0.5, 1.0 
mM).  Cells were sonicated and separated into pellet and supernatant.  This separation 
also aided in identifying the presence of cb5r and cb5 in either the pellet or the 
supernatant; since the two proteins are soluble, they were expected to be found in larger 
amounts in the supernatant. 
 The purification process started with the expression in E. coli of the inserted 
plasmid; later on the recombinant protein expression was achieved by the addition of 
IPTG, followed by sonication.  Finally, purification was obtained by Chitin Agarose 
Chromatography and Nickel Column Chromatography. 
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Methods 
 
 
 Vectors with the inserted clones were transformed in E. coli BL21 (DE3) RIPL 
competent cells and plated on TB agar containing 100µg/ml ampicillin.  Positive clones 
were selected from previously streaked backup plates and sent to Moffitt Core 
Sequencing Laboratory for sequencing.  Bacteria were grown overnight in 2ml LB broth  
with 75µl/ml of ampicillin; the sample was subsequently washed (minipreparation) with a 
series of buffers with the ultimate purpose of lysing the cells and cleaning DNA plasmids 
from proteins and other substances.  The following buffers in the following 
concentrations were added: 
- 300µl TENS Lysis buffer – to break the cells apart and release content 
- 150µl 3M NaAc – caused proteins that were present in the released content to 
precipitate and separate from DNA and forms a protein precipitate (solid) 
- 900µl 100% EtOH – helped precipitate DNA  
Following precipitation at – 20ºC for 15 minutes, pellet precipitate was washed first 
with 500µl 70% EtOH (cleans the plasmids from salts and buffers) followed by 500µl 
100% EtOH (dries up DNA and gets rid of water left on DNA from previous wash) 
DNA gel analysis was performed using Agarose Gel Electrophoresis to confirm 
the correct insert size in the pTWIN vector.  
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Optimization of Protein Expression 
 
  
 ∆P 138 P. falciparum cb5 and cb5r in E. coli BL21 (DE3) RIPL cells were grown 
overnight in 2mL TB-Amp75-chloramphenicol (Cm) 50µg/mL at 37°C and 250 rpm. A 
1:100 dilution of overnight culture was added to a 70mL fresh TB-Amp75 broth 
containing either 100µM riboflavin or 100µM ferric citrate; the sample was then grown 
for 2-2.5 hours at 37 ºC at 250 rpm until an Optical Density at 600 nm (OD600) was 
reached. IPTG was then added to the broths at concentrations of 0.2, 0.5, and 1.0mM and 
grown at either 37°C for another 3 hours or overnight (16 hours) at room temperature 
(23°C). In order to better localize our proteins, the cells were disrupted by sonication and 
centrifuged to separate pellet (P) and supernatant (S/N). SDS-Polyacrylamide Gel 
Electrophoresis was then performed in 4-20% acrylamide gels. 
 
Protein Purification 
 
 
The cells were harvested by centrifugation at 2500 rpm for 10 minutes at 4 ºC. The pellet 
was washed with PBS and the resuspended in lysis buffer. Cells were then sonicated and 
centrifuged at 10000 rpm for 5 minutes. The product is the separation of the sample into 
pellet and supernatant. Our proteins are soluble therefore we expect them to be found in 
the supernatant. The pellet was then washed with PBS to remove all traces of supernatant 
and spun. Pellet and supernatant are now ready to be run into a gel.  
 The proteins were further purified by two processes: Chitin Agarose 
Chromatography and Nickel (Ni-NTA) Column Chromatography. In Chitin Agarose 
Chromatography the protein passes through chitin resin beads which bind the target 
protein and the intein by the CBD.  Subsequently, the target protein is cleaved by the use 
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of a thiol-induced cleavage buffer of the intein, and the soluble protein of interest is 
eluted (Fig. 18).  In the purification process, a 200µl chitin bead slurry was spun at 10000 
rpm for 30 seconds.  The beads were washed with lysis buffer and added to the gel bed.   
After incubation, beads were washed again with lysis buffer for five times.  An additional 
wash with lysis buffer containing 40mM DTT was then applied.  Centrifugation led to a 
supernatant (elution 1), then addition of DTT buffer, incubation for 1 hour at room 
temperature, and subsequent centrifugation led to elution 2.  DTT buffer was added again 
and centrifuging led to elution 3.  
 Before being run through a nickel column, the protein was bound to the Histidine-
tag only.  The His-tag gave the protein an enhanced affinity that would aid in the 
purification.  Usually the target protein is the only protein in a mixture that would have 
such a strong bond to a long chain of histidine residues (usually six residues).  This tag 
has high affinity towards nickel.  When the protein is run through a resin with an 
abundance of nickel, the His-tag will bind the nickel and gets retained in the resin while 
all other proteins are will pass through.  Imidazole would then be added to the resin, 
which will compete with his-tags for nickel binding since they have similar structure.  
The protein was then released from the resin in a process called elution.  In the Ni-NTA 
column chromatography, the column was equilibrated with lysis buffer and centrifuged at 
2000 rpm for 2 minutes.  The lysate from chitin agarose purification was loaded into the 
column and allowed to sit for 30 minutes at room temperature.  The sample was then 
centrifuged again at 2000 rpm for 2 minutes and the column was washed with lysis 
buffer.  Finally the protein was eluted with elution buffer and spun as before, leading to a 
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supernatant (Ni-NTA elution 1).   Elution buffer was again added and centrifuging the 
sample led to elution 2.  A repeat of the same process led to elution 3. 
 
 
 
Figure 18: Protein Purification by Chitin Agarose Chromatography Using pTWIN 
Vector. 
Fusion of the intein protein to the C-terminus of P. falciparum cb5r target protein and release of the P. 
falciparum cb5r by thiol-induced cleavage. In this method, the target gene is cloned adjacent to an intein 
endoprotease (thiol inducible) linked to a chitin binding domain (CBD) that allows purification by chitin 
chromatography. Subsequently, thiol-induced cleavage of the intein releases the His6-cb5r or His6-cb5 
protein that is further purified by standard Ni-NTA column chromatography. 
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RESULTS 
 
The pTWIN vector containing both P. falciparum cb5r and cb5 genes, was 
transformed into E.coli BL21 (DE3) RIPL cells and confirmed by sequencing.  After 
minipreparation and digestion of minipreparation, an Agarose Gel Electrophoresis was 
performed to visualize if the inserts were successfully digested by restriction enzymes 
(Fig 19). 
 
Figure 19: DNA Gel of Cb5 Gene Coding Insert by Agarose Gel Electrophoresis. 
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In this DNA gel the first column is the DNA ladder, while the following columns represent four different 
plasmids that were picked by selecting four different bacterial colonies in TB agar. The top band with the 
red spot in all four pTWIN columns is the 5426 base pairs vector containing the insert. The bands with the 
green spot represent the 1234 base pairs insert. The cb5 is composed of 432 base pairs that are included in 
the 1234 base pair insert. 
 
 
Heterologous Expression of P. falciparum Cb5r Protein in E. coli 
 
 The expression of P. falciparum cb5r could not be achieved during this seven-
month project.  Numerous different experiments were attempted in order to optimize the 
expression of the protein but none of these succeeded.  One conclusion drawn from our 
studies and experiments was that Plasmodium cb5r may be toxic to the strain of E. coli 
used throughout our research.  Specifically it may use up or deplete the cells of crucial 
molecules, such as NADH, that play a role in vital biochemical processes.  In the same 
laboratory, a very similar result was observed in the expression of cb5r of the pathogenic 
fungus Cryptococcus neoformans  when the same strain of E. coli [E. coli BL21 (DE3) 
RIPL] was used for protein expression. Interestingly, cb5 expression was very abundant 
while cb5r expression was not obtained.  Since expression in the bacterium E. coli has not 
been successful for Plasmodium cb5r, one possible solution would be the use of a 
different organism, such as the fungus Pichia pastoris.  Plans have been made for this 
alternative future approach in the laboratory.  
Specifically, as for cb5 expression in E.coli, our first attempt of heterologous 
expression in Plasmodium cb5r was performed by (1) induction at various IPTG 
concentration (Fig. 20) followed by standard protein purification steps (Fig. 21).  Then a 
series of different assays were performed using different procedures with the goal of 
reaching optimal expression; (2) the addition of detergents during the purification steps 
(Fig. 22), (3) growth at different temperatures and for different incubation periods (Fig. 
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23), (4) growth in different media (Fig. 24), (5) addition of alcohol to the growth medium 
(Fig. 25), and (6) the screening of different bacterial clones (Fig. 26 & Fig. 27).  The 
results of these different optimization attempts are described in detail as follows: 
 
1) Optimization of P. falciparum cb5r protein expression using different concentrations of 
IPTG (0.2, 0.5, and 1.0 mM).  Also shown are the pellet and supernatant obtained by 
sonication of the cells (Fig. 20).  The samples were then purified by standard Chitin 
Agarose Chromatography and Ni-NTA Column Chromatography but no significant 
improvement was obtained; hence, the uninduced and induced samples looked the same 
(Fig. 21). 
 
2) Optimization of cb5r expression was performed by adding Triton X-100 and SDS 
detergents to the pellet and supernatant in order to solubilize the content, such as 
inclusion bodies, from the pellet.  The protein may be found in the pellet, therefore by 
solubilizing the content we may obtain a better yield of cb5r, but again, not differences 
could be observed (Fig. 22).  More specifically, proteins expressed with bacteria 
sometimes end up in inclusion bodies that serve as “waste compartment” for the bacteria.   
These inclusion bodies are usually found as a solid form or as precipitates, therefore the 
addition of detergent might help solubilize these structures and release the proteins (cb5r) 
into the supernatant fraction.    
 
3) Despite our finding that for most other protein expression experiments the optimal 
growth conditions were overnight (16 hours) culture at room temperature (23 ̊ C), growth 
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was also performed at 37 ºC for 2 hours to compare the outcomes.  It was thought that 
cb5r may need a more rapid and sudden expression to prevent bacterial degradation, but 
no substantial difference was found, and the bands corresponding to the molecular weight 
of cb5r have the same intensity for the two different growth conditions (Fig. 23). 
 
4) In the early stages of optimization of protein expression, two different growth media 
were used (LB broth and Terrific broth), and samples were selected at different times of 
incubation (30, 60, and 120 minutes).  LB broth is less rich in nutrients than terrific broth, 
to stimulate growth, hence this medium was chosen as an alternative to the nutrient-rich 
Terrific broth.  The rationale here is that since cb5r is toxic to E. coli, the protein may 
need a less powerful growth medium.  It could also be the case that cb5r needs less time 
for proper folding, after which it begins degrading.  Therefore three different expression 
times were chosen (30, 60, and 120 min).  Again, the two media and the incubation time 
at which the samples were collect did not affect expression of Plasmodium cb5r (Fig. 24). 
 
5) As a next step, two different temperatures were used (16ºC and 30ºC) with two growth 
media (LB and Terrific broth) and with different incubation times (30, 60, 120, and 180 
min).  Additionally, 2% ethanol was added to some of the growth conditions with the 
rationale that ethanol can substitute the lack of chaperone proteins in E. coli as a 
prokaryote, which can help facilitate protein folding in eukaryotic cells such as 
Plasmodium.  Ethanol can take the role of chaperones and aid in the protein 
folding/unfolding during cb5r expression in the heterologous bacterial system.    
Nevertheless, no significant differences in expression were observed (Fig. 25). 
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6) In figure 26a and 26b, twelve new clones were picked and run on a gel to compare 
them for protein expression levels with the previously picked clone, using Plasmodium 
cb5 as positive control for optimal protein expression (see next chapter on cb5 
expression).  Again, no difference was observed between any of the twelve newly picked 
additional clones when comparing uninduced and induced conditions on a protein gel 
(Fig. 26a and 26b). 
  
Molecular Weight of P. falciparum cb5r/Intein2-CBD: 66.17 kDa 
 
 
 
 
 
Figure 20: Optimization of P. falciparum Cb5r Protein Expression: Various IPTG 
Concentrations. 
Induction by IPTG at different concentrations (0.2, 0.5, 1.0mM) for 16 hours at 23 ºC. Also shown are the 
pellet and supernatant obtained after sonication of the bacteria. 
 
 
 
 
P. fal cb5r/Intein2-CBD 
66.17 kDa 
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Figure 21: P.falciparum Cb5r Purification Gel: Chitin Agarose and Ni-NTA 
Chromatography. 
Standard protein purification with Chitin Agarose and Ni-NTA Chromatography was performed with 3 and 
2 elutions, respectively. Since no significant results were observed in protein expression by IPTG 
induction, further purification did not show anything either. 
 
 
 
 
 
 
 
Figure 22: Optimization of P. falciparum Cb5r Expression Gel: Addition of Triton 
X-100 and SDS Detergents. 
Detergents were added to the pellet at 0.1% concentration to solubilize the content and “free” any protein 
trapped in inclusion bodies. The overexpressed protein may be found in the pellet, therefore by solublizing 
the pellet we may extract the protein but no differences are visible between the pellet and the supernatant. 
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Figure 23: Optimization of P. falciparum Cb5r Protein Expression: Growth at 
Different Conditions (Temperature and Incubation Period). 
Optimal growth was tested at two different temperatures and incubation periods (37°C for 2 hours and 
23°C for 16 hours) to see which of these two conditions positively affected expression. No significant 
differences were observed. 
 
 
 
 
 
 
Figure 24: Optimization of P.falciparum Cb5r Expression: LB Broth vs Terrific 
Broth. 
The use of more or less rich media can affect the proper expression of a protein. Since cb5r may be toxic to 
the bacterial cell, we tried to use an alternative less rich medium (LB broth) to compare it with expression 
in our standard medium (Terrific broth). No significant differences were observed. 
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Figure 25: Optimization of P. falciparum Cb5r: 16°C and EtOH. 
Growth was also tested at 16°C in both LB and Terrific broth. Furthermore, growth was performed with the 
addition of 2% ethanol to the growth medium at 30°C. Ethanol takes up the role of chaperones and is 
supposed to help cb5r fold and unfold properly since E. coli, being a prokaryote, lacks chaperones. In vivo, 
Plasmodium parasites, which are eukaryote organisms, use chaperones to perform such function but, since 
E. coli does not have chaperones, ethanol is thought to substitute chaperones. No significant differences 
were observed. 
 
 
 
 
 
Figure 26a: P. falciparum Cb5r Protein Expression: Screening of Clones 1 through 6. 
Six new clones were picked and run on a gel to compare their protein expression levels with the previously 
induced clone,  and cb5 as positive control that shows proper expression when compared with the 
uninduced sample. No significant differences were observed. 
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Figure 26b: P. falciparum Cb5r Protein Expression: Screening of Clones 7 through 
12. 
Six additional clones were picked and run on a gel to compare their protein expression levels with the one 
of the previously picked clone, using cb5 as positive control that shows proper expression when compared 
with uninduced bacteria. No significant differences were observed. 
 
Heterologous Expression of P. falciparum Cb5 Protein in E. coli 
 
Optimization of protein expression for ∆Lys44-cb5r-pTWIN and ∆Pro138-cb5-
pTWIN revealed that the optimal growth conditions are overnight (16 hours) culture at 
room temperature (23 ̊ C) at 100 rpm after being induced with 0.2mM IPTG.  After 
sonication, ∆Pro138-cb5-pTWIN is located in the cell lysate supernatant (Fig. 27).  
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Figure 27: Cb5 SDS-Polyacrylamide Gel Electrophoresis. 
The band that corresponds to cb5 (with His-tag, intein, and CBD still attached) is labeled in red and weighs 
44.78 kDa. This gel clearly shows the difference in expression between the uninduced (column 2) and the 
0.2, 0.5, and 1.0mM IPTG induced cb5 in columns 3, 4, and 5 respectively. Also included are the 0.2 and 
1.0mM IPTG induced pellet (columns 6 and 8 respectivvely) and the 0.2 and 1.0mM IPTG induced 
supernatant (columns 7 and 9 respectively) obtained after sonication. 
 
Further purification was achieved by Chitin Agarose Chromatography.  This 
purification breaks the bond between the Intein and the His-tag so that the protein (cb5) is 
left with only the six histidine residues attached (Fig. 28). 
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Figure 28: Cb5 Gel after Chitin Agarose Chromatography. 
This gel shows the difference in molecular weight in the cb5-Intein2-CBD that was induced by IPTG 
(column 3) and after sonication in the S/N (column 5), both with red stars, compared with cb5 after 
successful cleavage of intein and CBD (columns 6, 7, and 8 corresponding to elution 1, 2, and 3 
respectively) (black star). 
 
 We subjected cb5 through an additional purification through Ni-NTA Column 
Chromatography.  Here, the protein was separated from the His-tag and it became a 
completely pure protein.  Cb5 final molecular weight was calculated to be 16.94 kDa 
(Fig. 29).  
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Figure 29: Cb5 Gel after Complete Purification by Ni-NTA Column 
Chromatography. 
Bands in column 9 and 10 (red stars) represent the completely purified cb5. 
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DISCUSSION 
 
 
 Our main objective of expressing a recombinant protein generated ambiguous 
results, one of which was that the expression of cb5 was very successful.  The type of 
vector and the strain of bacteria used in cloning and expression of a recombinant protein 
gave positive outcomes with cb5 and the amount of protein yielded was extremely 
abundant.  On the other hand, the expression of cb5r was very problematic and could not 
be achieved.  Numerous attempts were made to achieve the expression of cb5r, but none 
was successful.  Several approaches were attempted but none of them worked.  
Transformation of plasmids into E. coli and protein expression was attempted twice from 
the beginning; it was thought at first that maybe the clones that were chosen had not 
picked up our gene.  The gel made after a new transformation attempt failed to show any 
differences between the uninduced and IPTG induced clones.  In another instance, 
expression by IPTG induction was aided by ethanol which was thought to promote 
protein expression, unfortunately however, the results did not change, and the protein 
failed to be expressed.  Additionally, the expression of cb5r was carried out at different 
temperatures and with different incubation periods but none of the assays produced 
satisfactory results.  A possible solution to achieve successful purification is to use a 
different organism for heterologous expression, such as the fungus Pichia pastoris.  
Given the time constraints, further experiments could not be performed and the 
biochemical and kinetic characterization of cb5r and cb5 would have to be conducted at a 
later time.  
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The future production of knock-outs of cb5r and cb5 will help us to identify which 
amino acids are responsible for the binding with the molecules with which they interact.  
This will aid to a more complete and thorough understanding of the biochemical and 
pharmacological characteristics of these two proteins. 
 In the context of public health, the identification of new successful drug targets 
for falciparum malaria will have great implications, the first and most important being the 
possible use of alternative drugs and the consequent alleviation of the current drug 
resistance.  As it was stated throughout the text, the emergence of resistance represents a 
huge obstacle in the cure of malaria, and this obviously leads to a greater number of 
deaths.  The first goal of public health is to prevent or at least reduce the number of 
deaths, therefore the discovery of new drug targets represents one of many methods that 
leads to the reduction of the burden of malaria worldwide.    
The successful expression of cb5r will certainly be achieved in the near future. In 
this way, the desired biochemical, kinetic, and pharmaceutical characterization will be 
investigated and a possible novel drug target discovered.   
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